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ABSTRACT OF THE DISSERTATION
Macrophage Proliferation Machinery Drives Immunosuppression and PDAC progression
by
Chong Zuo
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2022
Professor David G. DeNardo, Chair
Tumor-associated macrophages (TAMs) are abundant in near all solid tumors and are
involved in many aspects of cancer progression. The presence of TAMs is negative prognostic
indicator in several cancer types including pancreatic cancer. Attempts to target this population
by limiting their number in PDAC tumors have not achieved promising results, as compensatory
resistance pathways have already been defined. The heterogeneity of TAMs puts another barrier
into this targeting strategy, given macrophage subsets are important in maintaining tissue
homeostasis and some in performing anti-tumor functions. Previous studies have shown that
TAMs in PDAC tumors have dual origins – HSC-derived and embryonic-derived. Both subsets
of TAMs expand during tumor development and potentially have distinct functions. However,
the impact local proliferation might have on macrophage phenotype and cancer progression has
not been demonstrated. Here, we utilized genetically engineered cancer models, single-cell
RNA-sequencing data, and in vitro systems to show that proliferation of TAMs was driven by
colony stimulating factor-1 (CSF1) produced by cancer-associated fibroblasts. We further found
that a negative regulator of cell-cycle machinery, p21, was also induced by CSF-1 signaling
pathway. TAMs in human and mouse PDAC with high levels of p21 acquired a more
inflammatory yet immunosuppressive phenotype. The p21 expression in TAMs was induced by
both stromal interaction and/or chemotherapy treatment. Finally, by modeling p21 expression
levels in TAMs, we found that p21-driven macrophage immunosuppression in vivo promoted

x

tumor progression. Serendipitously, the same p21-driven pathways that drive tumor progression,
also cause responsive to CD40 agonist. These data suggest that stromal or therapy-induced
regulation of cell-cycle machinery can regulate both macrophage-mediated immune suppression
and susceptibility to innate immunotherapy.
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Chapter 1: Introduction
1.1 Overview of caner
1.1.1 Cancer and its logical frameworks
Cancer is the second leading cause of death in the United States and globally with an
estimated of 9.6 million deaths in 2018 (CDCBreastCancer, 2020; Cancer), which means every 1
in 6 death is coming from cancer (Global Cancer Facts & Figures | American Cancer Society).
Cancer is extremely difficult to treat with more than 100 distinct types of cancer and many
potential mutations associated with each cancer type. Furthermore, the total mutation events for
an individual tumor cell could be up to 11,000 (Stoler et al., 1999). As a result of these mutations
and their impacts on tissue homeostasis, a great number of complex regulatory circuits that link
numerous cellular players are altered and dysfunctional. It is a great challenge to understand how
many of these factors need to be targeted and which ones should be the priority.
In 2000, Hanahan and Weinberg proposed a logical framework for understanding the
progression of neoplastic diseases from normal cells. For a normal cell to become tumorigenic
and ultimately malignant, it needs to acquire a set of six traits including sustaining proliferative
signaling, evading growth suppressors, activating invasion and metastasis, enabling replicative
immortality, inducing angiogenesis and resisting cell death (Hanahan and Weinberg, 2000).
These six hallmarks focus on the changes in tumor cells themselves and provide a simplified, yet
complete, elucidation of cancer pathogenesis in the last decades.
In the next 20 years following the definition of “six hallmarks of cancer”, remarkable
progress has been made in cancer research, which has led to a development of the original
framework. Tumor is no longer an insular mass of proliferating cells, but complex tissues
1

comprised of multiple tumor-recruited or activated normal cell types. These cells, mainly
including fibroblasts and immune cells, along with the secreted factors from tumor-associated
stroma, actively participate in every aspect of tumor development (Hanahan and Weinberg,
2011). Tumor development is a process that not only includes a succession of genetic and
metabolic changes of tumor cells, but also a co-evolution of every cell type within the
environment (Hanahan and Weinberg, 2011).

1.1.2 Pancreatic cancer and current treatments
Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic
neoplasm and accounts for more than 90% of pancreatic cancer cases (Sarantis et al., 2020).
Approximately 60430 new diagnoses of pancreatic cancer were made in the U.S. in 2021 (Siegel
et al., 2021). Currently, PDAC is the third-leading cause of cancer mortality in the U.S. and the
seventh worldwide (Park et al., 2021). With the incidence of PDAC increasing by 0.5% to 1.0%
per year, in 2030, it is projected to be the second-leading causes of cancer death in the U.S.
PDAC carries one of the worst prognosis among all cancer types, with a five year
survival rate less than 10% in the past decades (Siegel et al., 2021). The high mortality is
attributed to several factors including late diagnosis, complex tumor biology and resistance to
multiple treatments. At the time of diagnosis, the majority of patients already have unresectable,
locally advanced disease (30-35%) or metastatic disease (50%), which leaves only 10-15% of
patients amenable to surgery. For patients with unresectable PDAC, conventional chemotherapy
is offered as a treatment modality. Frontline treatment options consist of gemcitabine plus
albumin-bound (Nab) paclitaxel (GEM/PTX) or FOLFIRINOX (Taieb et al., 2020). GEM/PTX
has been shown to significantly increase patient median survival to 8.5 months, as compared to
2

6.7 months in the gemcitabine alone group (Von Hoff et al., 2013). The multi-drug regimen
FOLFIRINOX, a combination of 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin, could
further increase disease-free survival to 21 months (Conroy et al., 2018). However, both
treatments are reported to be associated with higher rates of serious adverse effects and the
median survival time after treatment remains low when compared to other cancer types.
Radiation therapy (RT) is commonly used in cancer treatment. High-energy radiation
deposits energy and ions in the cells, causing DNA damage and blocking rapidly proliferating
cancer cells to divide and proliferate further (Baskar et al., 2012). RT is given as an adjuvant
treatment for PDAC patients following surgery and along with chemotherapy. Unfortunately,
conventional doses of RT after gemcitabine for unresected tumors largely failed (Hammel et al.,
2016; Loehrer et al., 2011). Recently, the advances in radiation oncology have allowed for
precise RT delivery to the pancreas at a higher dose, while sparing the adjacent luminal
gastrointestinal tract. This dose escalation approach has significantly increased patient outcomes
when compared to conventional RT (Reyngold et al., 2021).
Immunotherapy has shown impressive clinical benefit in several cancer types, especially
in melanoma. However, immunotherapy, including both PD-1/PDL1 antagonists, CTLA-4
antagonists, and the combination, has not demonstrated significant clinical activity in PDAC
(Beatty et al., 2017; Brahmer et al., 2012; Royal et al., 2010). The lack of efficacy observed with
these two immunotherapies has led to exploration of new strategies such as combining
checkpoint blockade with chemotherapy, which has yet to show benefits (Balachandran et al.,
2019).
In conclusion, current treatments for pancreatic cancer are still largely inefficient.
Patients with unresectable PDAC tumors are in a great need of new therapeutic approaches.

3

1.1.3 Pancreatic cancer tumor microenvironment
The field of oncology has evolved from solely focusing on the genetic alterations in
tumor cells to a broader and more accurate understanding of cancer as a complex “organ”.
Pancreatic cancer is one of the examples as it is characterized by extensive desmoplasia. The
desmoplastic stroma has been shown in multiple studies to facilitate tumor growth, promotes
metastasis, and acts as a biophysical barrier to therapeutic agents (Ho et al., 2020; Cannon et al.,
2018). Indeed, malignant cells often accounts for less than 20% of PDAC tissue mass, while the
remaining volume is occupied by fibroblasts, immune cells (predominantly myeloid lineages),
and extracellular matrix (ECM). All these cellular and non-cellular players interact closely with
the malignant tumor cells and provide survival benefits to the tumor cells.
PDAC fibroblasts are composed of several populations with different origins and
functions. Pancreatic stellate cells (PSCs), characterized by the expression of nestin, is quiescent
under normal condition. During tumorigenesis, they can be activated to a myofibroblastic state
and is responsible for most deposition of ECM proteins (von Ahrens et al., 2017). Inflammatory
fibroblasts are another type of fibroblasts that are commonly seen in PDAC tumors. They lack
elevated expression of -SMA, but instead express IL-6 and other inflammatory mediators
(Öhlund et al., 2017). These mediators can activate STAT3 signaling in both the tumor cells and
surrounding myeloid cells, which have shown to promote tumor growth (Panni et al., 2014).
Targeting ECM and fibroblasts has led to some successful examples of reducing tumor growth
and increasing responsiveness to chemotherapy in PDAC mouse models. However, some studies
also showed the opposite results after fibroblast depletion (Olive et al., 2009; Froeling et al.,
2011; Jacobetz et al., 2013). Therefore, a better understanding of the heterogeneity and function
of cancer associated fibroblasts is crucial for finding therapeutic strategies that target these cells.
4

Hypovascularity is another key feature of PDAC microenvironment, which is closely
interlinked with desmoplasia. Tumor samples show substantially lower microvessel densities
(MVD) than those of the normal pancreas (Feig et al., 2012), despite upregulation of
prototypically angiogenic VEGF pathway in tumor cells. This feature might explain why antiangiogenic therapies show generally low effects in pancreatic cancer (Kindler et al., 2010). In
human, directly measuring oxygen pressure in PDAC versus normal pancreas shows a significant
reduction in oxygenation, suggesting that PDAC tumor contains hypoxic areas (Koong et al.,
2000). Tumor cells adapted to hypoxic areas are more resistant to both chemotherapy and
radiotherapy and are more inclined to metastasize (Feig et al., 2012). The hypervascularity and
desmoplasia pose challenges to PDAC treatments, as they represent barriers to T cell infiltration
and drug delivery. The treatments that aim to directly kill tumor cells are blocked by the
desmoplasia and are also poorly delivery to the area due to lack of intact “normal” blood vessels.
Furthermore, immunotherapy that aims to stimulate CD8 effector functions and boost T cell
mediate tumor control is likely to fail, given the activated CD8 T cells might not be able to
infiltrate into the TME and come into close contact with the tumor cells.
PDAC tumor microenvironment (TME) is also immunosuppressive. Although substantial
number of immune cells that are supposed to recognize and eradicate tumor cells infiltrate into
the tumor, most of these immune infiltrates are hijacked by the tumor cells. Tumor cells recruit
the types of immune cells that are supporting their growth and suppress the ones that are not.
One major component of tumor recruited immunosuppressive immune cells is myeloid-derived
suppressor cells (MDSC), which could be further classified into two different types,
polymorphonuclear MDSC (PMN-MDSC) – morphologically and phenotypically similar to
neutrophils, and monocytic MDSC (M-MDSC) – morphologically and phenotypically similar to
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monocytes. CCL2 and CCL5 are the main chemokines to drive M-MDSC migration to the
tumors, whereas PMN-MDSCs are primarily recruited by CXC chemokines. Notably, these
recruitment factors are not specific for certain types of cancer and could be redundant in their
functions, which potentially acts as a resistant mechanism for therapeutic blockade of MDSC
recruitments. Another mature myeloid cell type that is often recruited by the tumor cells is
tumor-associated macrophages (TAMs). GM-CSF, G-CSF and M-CSF play important roles in
regulating and maintaining both MDSCs and TAMs. Extensive studies suggest that MDSCs and
TAMs share many immunosuppressive functions within the tumor microenvironment. Both are
capable of not only expressing molecules that inhibit effector T cell functions and expand
immunosuppressive TReg populations, but also directly or indirectly changing the tumor
microenvironment to further facilitate tumor growths. The impacts of TAMs on tumor
microenvironment and tumor progression will be further discussed in the next section (Bayne et
al., 2012; Siret et al., 2020; Gabrilovich et al., 2012; Kumar et al., 2016).

1.2 Overview of macrophages
1.2.1 Macrophage polarization and functions
Under normal conditions, macrophages are resident in all tissues and are important
mediators of tissue homeostasis. To ensure homeostasis, these cells are the main phagocytes that
remove and recycle enormous numbers of dead cells and debris, the active players that facilitate
healing and tissue regeneration, and the guardians that defend against bacterial infection. They
are also involved in the metabolism of nutrients like iron, calcium, lipid and amnio acid and
therefore, maintain fairly constant levels of these substances in the body.
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Macrophages are so versatile that can accommodate to specific tissue needs. Mosser et al.
propose that macrophages function as transducers in the body, which can sense the endless
variety of inputs from their environment and transduce these inputs into a variety of different
response outcomes (Mosser et al., 2021). DeNardo and Ruffell summarize the inputs into three
different categories: developmental origin, tissue of residence, and acute microenvironmental
cues. Upon receiving these inputs, macrophages have traditionally been contextualized within
the binary M1/M2 polarization system. When macrophages receive stimulation of
lipopolysaccharide (LPS) and IFN-, they increase expression of CD80, CD86, and MHC-II, and
release inflammatory cytokines and chemokines (for example, TNF-, IL-1, IL-1, IL-6, and
iNOS). This activation state is termed classically activated (M1) macrophage. Whereas, in the
presence of cytokines such as IL-4, IL-13, and TGF-, they express high levels of arginase-1
(ARG1), IL-10, CD163, CD204, or CD206 and play a major role in resolving inflammation,
would healing and tissue remodeling (Yao et al., 2019; Orecchioni et al., 2019; Mantovani et al.,
2004). However, increasing number of subsequent studies have shown that the binary M1/M2
system represents the two extremes of macrophage polarization states and does not recapitulate
most of in vivo settings due to macrophages constantly encountering a mixture of signals from
the nearby environment (DeNardo and Ruffell, 2019). The strategy of considering macrophage
activation states as a continuum of phenotypes is receiving increased acceptance.

1.2.2 Macrophage origin
Macrophages have long been hypothesized to originate from cells of the blood
compartment. They are recruited to the tissue sites with chemotactic signals released from local
cells. However, in the last few years, accumulating evidence calls this long-held view into
7

question by showing that a large portion of tissue-resident macrophages are established during
embryonic development, and self-maintain their number through proliferation, independently of
hematopoietic system (Ginhoux and Guilliams, 2016; Hashimoto et al., 2013; Schulz et al., 2012;
Yona et al., 2013; Jenkins et al., 2011). Under homeostatic conditions, tissue-resident
macrophages in most organs are derived from both sources with two exceptions – brain and
colon. Microglia in the brain are solely derived from embryo, whereas in colon, the embryonic
derived macrophages are rapidly replaced by HSC-derived monocytes. To maintain homeostasis,
macrophages from both origins acquire epigenetically-regulated program that indicates their
tissue residence, or in other words, environmental cues predominately determine macrophage
phenotypes (Lavin et al., 2014; Gosselin et al., 2014).
However, several recent studies including those from our own group have found that
TAMs from two origins not only co-exist in multiple tumor models but also function
distinctively. TAMs of HSC origin commonly upregulate genes associated with antigen
presentation, whereas these of embryonic origin are enriched in gene sets of tissue remodeling
and would healing. These observations suggest that macrophage origin could play an important
role in tumor immunity. However, the mechanism of how developmental origin would
epigenetically integrate with environmental cues remains unclear (DeNardo and Ruffell, 2019).
Also, researchers lack the tools to clearly distinguish long-lived monocyte-derived tissue resident
TAMs versus newly recruited and differentiated monocyte-derived TAMs. In addition, finding
human equivalent of two origins of TAMs is challenging. The evidence so far has relied on
discovering the conserved gene signatures of embryonic and HSC-derived TAMs, respectively,
in human PDAC patients (Mulder et al., 2021). Some pseudotime and velocity analyses have
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also been attempted, but none of the results are conclusive without actual tracking the bone
marrow cell development.
Despite the origins, notably, a significant portion of TAMs are actively proliferating in
PDAC. The impacts of local proliferation on sustaining macrophage number and on tumor
progression have largely been understudied. More specifically, the questions of whether
inhibiting macrophage proliferation could reduce total number of TAMs, and whether
macrophage proliferation machinery regulates macrophage phenotype to affect tumor immunity
and pancreatic cancer progression remain to be addressed. These questions will be further
elaborated upon the second section of this dissertation.

1.2.3 Macrophage metabolism
As discussed previously, pancreatic tumors are hypovascular and contains hypoxic areas,
which put survival challenges to both tumor and immune cells. Tumor hypoxia is commonly
observed in many cancer types. It happens when the demand for nutrients and oxygen from rapid
tumor cells proliferation exceeds the blood vessel growth, which usually activates cellular
programs to restore oxygen availability, including upregulation of angiogenesis factors,
metabolic reprogramming, and autophagy. However, the excessive angiogenic factors released
within the tumor microenvironment usually result in an aberrant vascular structure. Consequently,
the hypoxia condition persists, and only aggressive cancer cells are selected during the process.
Oxygen shortage could lead to generation of ROS, which increases genomic instability and
further accumulates the oncogenic drivers and accelerates malignant progression (Henze and
Mazzone, 2016).
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The metabolic shift of tumor cells in hypoxic region has first been described by Otto
Warburg in 1924 and referred it as the “Warburg effect”. This effect entails a shift from
oxidative phosphorylation (OXPHOS) as the main source of generating ATP to anaerobic
glycolysis (Crezee et al., 2020). Subsequent studies identify several key factors regulating this
process, for example, hypoxia-inducible factor-1a (HIF-1). HIF-1 binds to glucose transporter
GLUT1 and glycolytic enzymes, induces expression of lactate dehydrogenase (LDH), and
pyruvate dehydrogenase kinase, which all promote metabolic shift to anerobic glycolysis.
TAMs in hypoxic areas exhibit the type of metabolic reprogramming reminiscent of the
tumor cells, as an increase in glycolysis but decrease in OXPHOS. Such metabolic
reprogramming has been shown to drive TAM immunosuppression and promote PDAC growth
and metastasis (Penny et al., 2016; DeNardo and Ruffell, 2019). Mechanistically, tumor cells and
stromal cells express higher level of macrophage migratory and survival factors, such as CCL2,
CCL5, CSF-1, and angiogenic factors, VEGFA, which recruit macrophages to the hypoxia
regions. Then the accumulation of lactate within the area due to increased glycolysis from TAMs
promotes expression of HIF-1a, arginase, and also glucose transport, which subsequently create a
pro-inflammatory but immunosuppressive microenvironment. TAMs in regions of hypoxia also
expressed lower level of MHC-II compared to those in normoxic conditions (Movahedi et al.,
2010), further suggesting their immunosuppressive phenotype. In a very recent study, lactic acid
resulting from a glycolytic environment could be absorbed by Treg cells and enhance their
expression of PD-1, therefore inhibiting the efficacy of immunotherapy (Kumagai et al., 2022).
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1.3 Targeting tumor associated macrophages
1.3.1 TAMs and cancer initiation
Macrophages are a major component of the leukocyte infiltrate that is present to a widely
carrying extent, in all types of malignancy, including tumors. The presence of TAMs is
commonly correlated with worse patient outcomes, largely due to their contribution at different
levels: by promoting cancer initiation and growth, supporting metastasis, stimulating
angiogenesis, and taming protective adaptive immunity. Tumor initiation requires gain-offunction mutations in oncogenes or loss of function mutation in suppressor genes, which permit
cells to develop into malignancy. Studies have shown that less than 10% of all cancers are
caused by germline mutation; the remainders are caused by acquired mutations throughout
lifespan (Elinav et al., 2013). In 1986, Dr. Dvorak proposed an idea that tumors are wounds that
do not heal, emphasizing the similarity between the processes of wound healing in chronic
inflammation and of cancer development (Dvorak, 1986). Both processes can be viewed as a
dysregulated form of protective response to a loss of tissue homeostasis. Indeed, persistent
inflammatory responses, such as obesity, chronic bacteria or virus infection, and Crohn’s disease
have shown to dramatically increase the risk of cancer.
Macrophages promote tumor initiation as they actively regulate inflammatory responses
by production of various cytokines including IL-6, TNF- and interferon-. To list a few of the
examples, IL-6 could activate STAT3 signaling to promote cell proliferation and inhibit
apoptosis, which has been shown to be critical in the early tumorigenesis of colitis-associated
colorectal cancer (Bollrath et al., 2009; Grivennikov et al., 2009). Similarly, another group has
shown that STAT3 has an intrinsic role in pancreatic intra-epithelial neoplasia development
(Fukuda et al., 2011). NF-B is another important molecule that could be activated by IL-6 and
11

TNF-, linking chronic inflammation to cancer. Activation of NF-B is necessary for host
defending against infections and maintaining tissue homeostasis, however, prolonged and
dysregulated activation has often been observed in tumor cells and in the tumor
microenvironments of most solid cancers (Taniguchi and Karin, 2018). NF-B activation
promotes the production of reactive oxygen species that cause DNA damage and oncogenic
mutations. A study shows that depletion of IKK, the activator of NF-B signaling, in intestinal
epithelial cells dramatically decreases tumor incidence (Greten et al., 2004). Similarly,
suppressing NF-B activation through anti-TNF treatment or induction of IB inhibits
hepatocellular carcinoma development (Pikarsky et al., 2004). Furthermore, NF-B is activated
in TAMs, and by blocking its activation, TAMs can be converted to a more cytotoxic phenotype
and cause tumor shrinkage (Greten et al., 2004; Porta et al., 2009; Hagemann et al., 2008). A
third mechanism of TAMs driving tumor initiation is through NLRP3 inflammasome. TAMs
have shown promoting lung tumor formation by inducing IL-1 and IL-1 production through
TLR signaling. These two inflammatory mediators along with CCL2 and TNF- are known to
support development of lung and colon cancer (Ge and Ding, 2020).

1.3.2 TAMs and cancer development
The factors discussed previously could also be the driving force of cancer development.
In addition, TAMs in a chronic inflammatory microenvironment could be immunosuppressive
and facilitate tumor escape from immunosurveillance. TAMs express an array of molecules that
directly inhibit the anti-tumor immune response of T cells or recruit other cells to suppress tumor
immunity. Extensive ex vivo studies have shown that TAMs can suppress naïve T cell
proliferation. One of the mechanisms is thought to be that murine macrophages deplete L12

arginine by the expression of arginase-1. L-arginine is needed by T cells for their survival and
proper anti-tumor activity (Geiger et al., 2016). Expression of arginase is high in tumor samples
of patients with non-small cell carcinoma, and interrupting arginase expression in vivo reduced
lung tumor growth (Rodriguez et al., 2004). In addition, enhanced arginase expression in
macrophage also increases production of tumor promoting polyamines and decreases tumoricidal
nitric oxide in vitro. Therefore, these data suggest, TAMs could directly suppress T cell function
and promote tumor growth through high expression of arginase-1.
TAM’s expression of nitric oxide synthase (iNOS/NOS2) is another important factor of
restricting T cell function. NOS2 catalyzes L-arginine to produce nitric oxide (NO). Studies
suggest that NO directly competes with O2 for cytochrome c oxidase (CcO) binding, causing
redistribution of intracellular oxygen, subsequent stabilization of HIF-1 expression and
activation of downstream pathways (Olson and van der Vliet, 2011). As a consequent, NO
compounds the signaling consequences of hypoxia and tumor cell metabolism (Hagen et al.,
2003). Studies have also shown that TAMs expressing arginase and NO directly induce T cell
apoptosis in an ex vivo setting (Kusmartsev and Gabrilovich, 2005), and are able to protect tumor
cells from chemotherapy induced apoptosis(Perrotta et al., 2018). Furthermore, NO affects the
concentration of reactive nitrogen species (RNS). One study shows that RNS induces CCL2
chemokine nitration and promote infiltration of TAMs other than tumor specific T cells.
Inhibiting CCL2 nitration significantly increase cytotoxic T cell infiltration (Molon et al., 2011).
Another important aspect of immunosuppression driven by TAMs is through recruitment
of immunoregulatory Treg. In ovarian carcinoma, all tumor Treg cells express CCR4 and could be
recruited by CCL22 present in the tumor ascites. TAMs are shown to be the main producer of
CCL22 in this cancer model (Curiel et al., 2004). Induction of CCL22 production has been
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shown to be dependent on NF-B signaling pathways which are commonly activated in cancers
(Sun et al., 2016).
Rather than affecting T cell function and recruitment, TAMs could also be involved in
shielding tumor cells from T cell contact by modulating fibrosis. Under normal conditions,
macrophage phenotypic changes from pro-inflammatory to anti-inflammatory are indispensable
for proper tissue repair and resolving later stages of infection. However, the same mechanism
and activated pathways could also drive tumor fibrosis. Strong evidence shows that macrophages
could activate and recruit myofibroblasts by the production of pro-inflammatory cytokines such
as TNF- and IL-1, and CCL2 or granulin, respectively (DeNardo and Ruffell, 2019; Braga et
al., 2015). TAMs are also one of many cells that produce TGF1, which functions as the primary
mediators of TGF signaling (Pickup et al., 2013). Overexpression of TGF has been broadly
observed in desmoplastic stromal environment, in which increased TGF signaling corresponds
well with fibroblast activation and differentiation as well as ECM deposition. Notably, TGF has
previously been shown reduce DC and macrophage antigen-presentation, suppress NK cells,
neutrophils, TH1 cells anti-tumor function and promote TH17 cells differentiation (Pickup et al.,
2013). In addition, TAMs secrete metalloproteinases, including MMP-9 and MMP-2 that
degrade ECM and promote EMT. Blocking MMP-9 or MMP-2 leads to reduction of fibrosis
(Quintero-Fabián et al., 2019).

1.3.3 Targeting TAMs in PDAC
Given TAMs promote cancer developments through many aspects, a considerable
number of studies have investigated targeting this population. Here, we only list the attempts
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which have been made in treating pancreatic cancer. In pancreatic ductal adenocarcinomas
(PDACs), the presence of TAMs is correlated with poor clinical outcomes. The approaches that
are tested preclinically and clinically include mainly two strategies – limiting the total number of
TAMs within PDAC tumors or altering TAMs activation states toward more antitumoral. The
prior includes targeting CCL2-CCR2 signaling that is required for monocyte trafficking into the
tissue, and CSF1-CSF1R axis that is needed for macrophage survival and proliferation. In animal
models, both strategies have shown reduced number of TAMs within the tumor and increased T
cell infiltration and response, as well as improved efficacy of chemotherapy, radiation therapy
and immunotherapy (Mitchem et al., 2013; Nywening et al., 2016; Sanford et al., 2013; Connolly
et al., 2016; Zhu et al., 2014, 1).
Despite promising results in animal models, targeting these two pathways, although
capable of reducing macrophage number within the tumor, generally have shown limited
therapeutic efficacy when being used alone or being combined with immuno/chemotherapy in
clinical trials (Lopez-Yrigoyen et al., 2021; Ho and Jaffee, 2021).

Translation of these

approaches have met two major barriers; one is that compensatory resistance pathways have
already been defined — increase in immunosuppressive PMN-MDSC, and second is that
macrophage depletion strategies also depletes tissue-resident populations that are important for
maintaining homeostasis.
These results led to the hypothesis that depleting TAMs might not be the optimal strategy.
The field is now exploring the possibility of reprogramming TAMs from a pro to an antitumoral
phenotype. CD47 is overexpressed across multiple tumors and inhibits macrophage phagocytosis
(Cassetta and Pollard, 2018). In in vitro models, CD47-blocking antibodies significantly
improved macrophage phagocytosis of patient-derived PDAC cells, and prolongs tumor bearing
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mice survival (Michaels et al., 2018). The efficacy in treating human patients has yet to be tested.
Another extensive studied agent is anti-CD40 antibody. CD40 is widely expressed by antigen
presenting cells and belongs to the TNF receptor superfamily. Once CD40 interacts with its
natural ligand CD40L, it upregulates the expression of MHC molecules, costimulatory molecules,
and proinflammatory cytokines, which are important for T-cell activation. CD40 agonists mimics
the signal of CD40 ligand. In GEMMs, it induces both T-cell-dependent and T-cell-independent
tumor control (Beatty et al., 2011; Vonderheide et al., 2013). TAMs are required in CD40
mediated tumor regression with reported upregulation of MHC class II, CD86 and secreted levels
of TNF-, IFN-, and enhanced T cell activation. Depletion of TAMs abrogates CD40 agonist
effect, while depletion of CD4 or CD8 T cell does not. Currently, several clinical trials are
ongoing exploring the efficacy of CD40 alone or combining with chemotherapies
immunotherapies in treating several cancer types (Duan and Luo, 2021).

1.4 Overview of Cell-cycle
1.4.1 Cell-cycle phase and its regulation
Cell division describes a process which consists of DNA replication and segregation of
replicated chromosomes into daughter cells (mitosis). This process can be further divided into
four different phases: mitosis (M phase), characterized by nuclear division, and three interphases
(G1, S and G2 phases), which include all the preparations before mitosis and are characterized
by DNA replication and growth of cell size. These four phases constitute the classic division of a
cell cycle (Vermeulen et al., 2003). Notably, not all cells within an organism are actively
proliferating. Mature and fully differentiated cells generally stay at a resting state called G0.
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The accurate transition from every cell cycle phase is crucial for cells to avoid
oncogenesis, and therefore this process is tightly controlled by a regulatory network that is
conserved from yeast to human. Many cell cycle factors are involved in this network, namely
cyclins, cyclin-dependent kinases (Cdks), cyclin-dependent kinase inhibitors, and ubiquitin
ligases. Cdks are serine/threonine kinases and are activated by binding of cyclins. Specific Cdkcyclin complexes drive cell cycle progression in a sequential and orderly fashion. Throughout
evolution, the number of Cdks and cyclins increases while the generally mechanism is preserved
(Malumbres and Barbacid, 2009; Ogasawara, 2013). Briefly in eukaryotic cells, mitogenic
signals increase the expression of D-type cyclins (D1, D2 and D3) which bind and activate Cdk4
and Cdk6 during G1 phase. Activation of cyclin D- Cdk4/6 complex phosphorylates
Retinoblastoma (Rb) protein and results in the release of transcriptional factor - E2F and the
transcription of E2F controlled genes. Cyclin E, one of the E2F induced proteins, binds and
activates CDK2, which further feedbacks to Rb phosphorylation and E2F release, allowing for S
phase entry (Vermeulen et al., 2003). CDK2 is subsequently activated by cyclin A at late S phase
and mediate cells transit to G2 phase. At G2 phase, CDK1 is activated by cyclin A and facilitate
the onset of M phase. Lastly, CDK1-cyclin B complexes drive cells through mitosis and finish
one cell cycle (Malumbres and Barbacid, 2009).
Beside positive regulation from cyclin-CDK complexes, cyclin-dependent kinases
inhibitors (CKIs) provide an extra negative regulation of the cell cycle. CKIs are separated into
two classes based on structure and Cdk specificity: Ink4 and Cip/Kip. Members in Ink4 family
including p16INK4a, p15 INK4b, p18 INK4c and p19 INK4d, primarily bind and inhibit Cdk4 and 6. The
Cip/Kip family consists of p21Cip, p27Cip, and p57Cip. These proteins have broad inhibition
spectrum and interact with many cyclin-Cdk complexes (Lim and Kaldis, 2013).
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Recent advances in technology of single-cell labeling and time-lapse fluorescence
microscopy have made it possible for the observations of protein dynamics at single cell
resolution. These technology inventions led to a revisit of the cell cycle events which are
observed in averages of cell population by immunoblots. Some observations were confirmed by
the new technologies, for example, the negative feedback loop of p53-Mdm2 upon DNA damage
and cell cycle arrest (Lahav et al., 2004). New technologies also provide fundamental novel
insights into the field. One of them is the stochasticity in gene expression despite constant
environmental conditions (Kærn et al., 2005). Fitting to the same idea, the expression of cellcycle-dependent (CCD) genes and proteins are heterogeneous among same cell population. Cell
cycle fate is determined not simply by the expression of one or two regulators but by converting
the signals from multiple sources to a dynamic equilibrium of cyclin D1 and p21 (Spencer et al.,
2013; Yang et al., 2017a). Hundreds of previously undescribed cell cycle regulators were found
to be associated with cell proliferation in a Huma Protein Atlas study last year (Mahdessian et
al., 2021).

1.4.2 p21 and its function
Back to 1990s, David Beach’s lab identified a 21kd protein(p21) that is present in the
cyclin-CDK protein complexes (Xiong et al., 1992). Soon after, Stephen J. Elledge’s group
showed that p21 is found to be associated with multiple cyclin-CDK complexes and inhibit the
phosphorylation of Rb (Wade Harper et al., 1993). In the same year, David Beach’s lab further
found p21 inhibits the activities of each member of the cyclin/CDK family, indicating that p21
maybe a universal inhibitor of cyclin kinases (Xiong et al., 1993). Interestingly, p21 also found
to be an adaptor protein for the assembly of CDK4-cyclinD complex in both epithelial cells and
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fibroblasts, which increase the affinity by 35 fold (LaBaer et al., 1997; Cheng et al., 1999). The
effects of p21 on cell-cycle is concentration dependent, as high concentration inhibits cell cycle
progression while low concentration promotes.
p21 is critical for the DNA damage response. DNA double-strand breaks (DSBs) pose the
greatest challenge to cells. When it happens, it is necessary for the cell to pause and fix the errors
before going into the next cycle or being terminated if the problems cannot be solved. A crucial
player to fulfill these functions is p53, which activates downstream genes that lead to cell cycle
arrest, senescence, and apoptosis. Many of these functions are through p21. p21 is necessary and
sufficient for p53-dependent repression of genes associated with cell-cycle progression and antiapoptosis(Abbas and Dutta, 2009; Georgakilas et al., 2017). p21-deficient cells show
compromised or completely loss of G1 arrest (Gartel and Tyner, 1999). Notably, for cell to
reenter cell cycle after S phase block, p21 levels have to decrease (Gottifredi et al., 2004). This is
confirmed by recent studies, in which endogenous expression of CDKN1A at single-cell level is
monitored by an insertion GFP tag. The levels of p21 are heterogenous within a same population
of immortalized epithelial cells, however, p21 is consistently absent in all cells during S-phase.
Degradation of p21 is important for G1/S transit and there is a strong correlation between the
levels of p21 and the length of G1 phase (Barr et al., 2017). Furthermore, p21 could be passed
from mother cell directly into the daughter cells and could also determine the latter’s cell fate –
either to proliferate or being quiescent (Arora et al., 2017).
Studies also have reported that p21 plays a key role in inhibiting apoptosis and protecting
cells from death. p21 is shown to maintain cell viability after DNA-damage (Yosef et al., 2017).
Such mechanism could also be carcinogenic and could lead to therapy resistance. p21 is reported
to maintain self-renewal of leukemia stem cells and prevent excess DNA-damage (Viale et al.,
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2009). Following up on the similar idea, one recent study shows that the extent of DNA damage
after chemotherapy is linked to cellular p21 level; cells with low level of p21 has higher level of
DNA damage (Hsu et al., 2019). The study proposes a “Goldilocks zone”, indicating the levels
of p21 at the time of receiving environmental challenge or therapeutic intervention determines
the ultimate fate of continuous proliferation or being senescence. These data suggests that any
factor that potentially affects expression level of p21 could affect therapeutic efficacy.

1.4.3 Regulations of p21
Given that p21 regulates critical cell event and cell fate, its expression and activity are
tightly controlled by various factors. p21 promoter contains two conserved p53 responsive
elements and therefore directly responds to p53 regulation. When cells sense harmful signals
such as DNA damage or oxidative stress, they upregulate p53 activity which subsequently induce
p21 and cell cycle arrest. Besides p53, recent studies show that overexpression of integrin 1
subunit increases p21 promoter activity by recruiting the Sp1 transcription factor and
transcriptional co-activator P300. TGF- also regulates p21 expression by phosphorylation of
SMADs and activation of MAPK signal pathway. On the other hand, ligase ubiquitination and
proteasomal degradation are two mechanisms to downregulate p21 activation. In addition, c-myc
family of proteins can represses the expression of p21 at transcriptional levels.

1.4.4 p21 functions in macrophages
In addition to cell-cycle control, a few studies have reported that p21 potentially regulates
inflammatory response. The most established role of p21 is in the model of LPS-induced septic
shock. p21-/- mice shows increased susceptibility to endotoxic shock (Trakala et al., 2009;
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Mavers et al., 2012). The reason is thought to be associated with increased NF-b activation in
macrophages, which subsequently secrete more IL-1 (Scatizzi et al., 2009). Blocking p21 in
macrophage reduced IL-1 secretion. A recent study suggest that rather than simply blocking or
activating NF-B signaling, p21 affects the binding affinity between p50-p50 dimer to DNA and
therefore adjusts the equilibrium between p65-p50 and p50-p50 pathways to mediate
macrophage plasticity in LPS tolerance (Rackov et al., 2016). This mechanism fits well to
macrophage capability of shifting between inflammatory and immunoregulatory. However, by
far, there is no clear evidence to show that p21 directly binds to the components within NF-B
pathway and how it potentially affects p50 binding affinity to DNA. Indeed, results from
knocking p21 have been controversial; p21-/- mice suffer more severe inflammatory arthritis and
articular destruction (Mavers et al., 2012). In contrast, disruption of p21 attenuates lung
inflammation in mice (Yao et al., 2008). In summary, these data suggest that p21’s effects on
inflammation are context and environmental cues dependent. Although these effects are related
to, likely not through a direct interaction with NF-B components.
In a chronic pancreatitis model, p21 expression is significantly increased overall, while
knocking-down its expression resolves inflammation and prevents pancreatic injury through
reducing the release of NF-B-mediated proinflammatory cytokines, such as TNF-, IL-6, and
CXCL1 (Seleznik et al., 2018). These data suggest that at least in the pancreas, p21 could play a
role in promoting inflammation, independent of KRAS mutations that are commonly observed in
PDAC and are known to drive inflammation (Kitajima et al., 2016). However, this study does
not identify the main drivers for p21-mediated inflammation.
In summary, macrophages are a highly plastic innate immune subset that could adapt
their phenotypes across a spectrum of activation states, which also enable them to be involved in
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almost every aspect of cancer development. Proper activation and regulation of inflammatory
response is tightly associated with tumor immunity and tumor control. p21, one of the cell cycle
regulators, is reported to affect the extent of inflammatory response under different pathology
conditions, particularly in macrophages. These observations raise the fascinating questions of
how p21 expression in TAMs could affect their proliferation, number, and phenotype,
consequently, how these changes in TAMs would affect tumor immunity and tumor progression.
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2.1 Focused introduction:
Macrophages are one of the most abundant immune cell types in the tumor
microenvironment (Noy and Pollard, 2014). Extensive studies have shown that macrophages can
mediate tumor immunosuppression by both directly interacting with cytotoxic T cells and
indirectly affecting T cell functions through secretions of immuno-modulators that create a
favorable tumor microenvironment (DeNardo and Ruffell, 2019; Cassetta and Pollard, 2018;
Doedens et al., 2010). Aside from their immunosuppressive phenotypes, macrophages are known
to promote tumor initiation, angiogenesis, local invasion, and metastatic spread (Ruffell and
Coussens, 2015; Hao et al., 2012; Cassetta and Pollard, 2018). Unsurprisingly, the presence of
macrophages is found to be associated with a poor clinical outcome in many cancers, including
pancreatic cancer (Cassetta and Pollard, 2018; Ino et al., 2013). As such, preclinical and clinical
studies have focused on targeting tumor-associated macrophages (TAMs). These approaches,
often consisting of macrophage-depleting strategies, have yet to show clinical success, in spite of
showing efficacies in preclinical models (DeNardo and Ruffell, 2019; Cannarile et al., 2017; Poh
and Ernst, 2018; Xiang et al., 2021). This suggests more studies are needed to understand the
varied subset of macrophages in tumors and how they impact tumor immunity and cancer
progression.
During tissue damage, macrophage numbers can be increased by multiple mechanisms.
These include the expansion of tissue resident macrophage populations by local proliferation or
new macrophages can be recruited from blood monocytes (Ginhoux and Guilliams, 2016). This
balance is likely regulated by both the tissues and types of damage. In pancreatic ductal
adenocarcinoma (PDAC), macrophages are derived from both monocyte and tissue resident
sources (Zhu et al., 2017). One consistent characteristic of TAMs from both sources in PDAC
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mouse models is that they are highly proliferative (Zhu et al., 2017). Notably, proliferation of
macrophages is not only observed in tumors, but also in injured and inflamed tissues (Hashimoto
et al., 2013; Davies et al., 2011; Van Gassen et al., 2015). Under these conditions, inhibiting
macrophage proliferation dramatically reduced macrophage number and inflammation (Tang et
al., 2015). These observations raised the possibility that inhibiting macrophage proliferation in
PDAC might limit the number of tumor-promoting macrophages.
Macrophage proliferative status is commonly associated with underlying macrophage
phenotypes. Interferon gamma (IFN-) and lipopolysaccharide (LPS) inhibit macrophage
proliferation and induce production of nitric oxide (NO) and inflammatory cytokines (Müller et
al., 2017; Xaus et al., 2000; Marchant et al., 1994). Interleukin (IL)-4 promotes macrophage
proliferation and drives them to a TH-2 like phenotype (Jenkins et al., 2013). These observations
led to the question of whether the macrophage proliferation machinery plays a role in regulating
macrophage phenotypes.
In this study, we aimed to understand how the PDAC microenvironment drove local
macrophage proliferation and what the net outcome of this was on tumor immunity and
progression. We discovered that while cancer-associated fibroblast-induced macrophage
proliferation was important for sustaining TAM number, induction of p21 in TAMs by stromal
colony stimulating factor-1 (CSF1) resulted in immunosuppression and tumor progression.
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2.2 Result:
Tumor infiltrating macrophages are highly proliferative in PDAC.
To

evaluate

human

PDAC

infiltration

by

TAMs,

we

utilized

multiplex

immunohistochemistry (mpIHC) to stain for CD68+ macrophages and CK19+ tumor cells in
human PDAC tissues and found that CD68+ TAMs were more frequent in PDAC tissues when
compared to adjacent normal pancreas tissues (Fig. 2.1 A). To further study infiltrating
macrophages, we utilized a p48-Cre+/LSL-KrasG12D/p53flox/flox (KPC) genetically engineered
mouse model (GEMM), which spontaneously develops PDAC tumors and recapitulates the
pathological features of human PDAC(Hingorani et al., 2003, 2005). As in human PDAC, we
found that the number of F4/80+ TAMs increased paralleling disease progression (Fig. 2.1 B and
C). Our previous studies have shown that these PDAC infiltrating TAMs were sustained by both
local proliferation and monocyte recruitment in animal models(Zhu et al., 2017). However, these
studies did not assess the potential impact macrophage proliferation might have on tumor
progression or tumor immunity.
To further investigate the significance and mechanisms of local proliferation of TAMs,
we more deeply studied pancreatic tissues from GEMMs and human PDAC patients. We first
evaluated the frequency of proliferating macrophages in human PDAC tumors by mass
cytometry time of flight (CyTOF). Distinguishing major leukocyte populations based on surface
markers, we found that CD68+CD64+ macrophages composed >15% of all infiltrating leukocytes
(Fig. 2.1, D and E and Fig. 2.9 C). Notably, these macrophages expressed high levels of the
proliferation markers PCNA and Ki67 (Fig. 2.1 D). Ki67+ macrophages made-up 20% of total
macrophages, and this percentage was significantly higher than that of other leukocyte
populations, such as neutrophils (Fig. 2.1 F and Fig. 2.9 B). Next, we examined proliferating
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macrophages in tumors from KPC GEMMs. We observed >10% of F4/80+ cells were also
Ki67High by mpIHC analysis (Fig. 2.1, I and J). The number and proliferation of TAMs were
consistent in both p53flox/+ and p53R127H/+ orthotopic models (Fig. 2.1, K and L). In addition, we
generated and analyzed single-cell RNA-sequencing(scRNAseq) data from normal pancreas,
pancreatic tissues from KPC GEMMs, orthotopic PDAC tumors, and previously published
human PDAC datasets(Peng et al., 2019) (Fig. 2.1 G). In human PDACs, we found populations
carrying both myeloid and proliferating signatures (Fig. 2.1, H). Similarly, in mouse datasets, we
identified TAMs independent of cell cycle genes (Fig. 2.9 F), then upon reclustering, we easily
identified discrete clusters with cell cycle gene signatures (Fig. 2.1 M). As expected, this cluster
was expanded in PDACs compared to normal tissues (Fig. 2.1 N). Taken together, these data
suggest that a significant portion of macrophages are actively proliferating in both murine and
human PDAC tissues.

Cancer-associated fibroblasts drive macrophage proliferation through CSF1.
To identify the cellular players that drove macrophage proliferation in PDAC, we
investigated the cellular composition in the PDAC tumor microenvironment (TME). As others
have shown, PDAC tumors contain dense fibrotic stroma(Elyada et al., 2019; Schnittert et al.,
2019; Waghray et al., 2013), and immunohistochemistry (IHC) staining of PDAC tissues from
KPC GEMMs revealed abundant PDPN+ cancer-associated fibroblasts (CAFs) surrounding
CK19+ tumor cells (Fig. 2.2 A). We next performed proximity analysis and found that TAMs
were within 100 µm to both tumor cells and CAFs, but more frequently closer to PDPN+ CAFs
than CK19+ tumor cells (Fig. 2.2 B). To test whether CAFs and tumor cells drove macrophage
proliferation, we co-cultured bone marrow-derived macrophages (BMDMs) with either PDAC
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cell lines from KPC GEMMs or primary pancreatic fibroblasts. We found that PDAC cells and
fibroblasts both led to increases in macrophage proliferation, as measured by BrdU
incorporation. However, fibroblasts induced significantly higher levels of proliferation and
increases in the number of macrophages (Fig. 2.2 C). Additionally, macrophage proliferation
was not further enhanced by triple culture of PDAC cells and fibroblasts, suggesting the effects
were not additive (Fig. 2.2 C, grey bars). To determine if fibroblasts induced macrophage
proliferation in a cell contact-dependent manner or through secreted factors, we repeated these
assays in a Transwell system. We found that without direct contact to BMDMs, fibroblasts still
drove macrophage proliferation at almost a comparable level as the strong mitogen, CSF1 (Fig.
2.2 D).
To identify the relevant secreted factors from fibroblasts that drove macrophage
proliferation, we profiled 111 soluble factors derived from KP-1, KP-2, or fibroblast-conditioned
media and found that fibroblasts secreted significantly higher levels of CSF1 (Fig. 2.2 E). We
measured the levels of CSF1 secreted by fibroblasts and three different PDAC cell lines (KP-1,
KP-2, and KI) through ELISAs and confirmed that only fibroblasts produced high levels of
CSF1 (Fig. 2.2 F). Next, we sought to determine if CSF1 was necessary and sufficient for
fibroblasts to drive macrophage proliferation. Both the addition of neutralizing CSF1 IgG to the
co-culture of BMDMs and fibroblasts and knocking-down CSF1 in fibroblasts by siRNA in
Transwell assays, resulted in a loss of fibroblast-driven macrophage proliferation and number
expansion (Fig. 2.2, G, H and I). These data suggest that CSF1 secreted from fibroblasts is both
necessary and sufficient to macrophage proliferation in vitro.
To confirm CAFs drive TAMs proliferation in in vivo pancreatic tissue, we analyzed
scRNAseq datasets from both mouse and human. In a previously published dataset (Hosein et al.,
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2019) of pancreatic tumors from three GEMM models, including KrasLSL-G12D/+Ink4afl/fl/Ptf1aCre/+
(KIC), KrasLSL-G12D/+Trp53LSL-R172H/+Ptf1aCre/+ (KPR172H/+C), and KrasLSL-G12D/+Trp53fl/fl/Pdx1Cre/+
(KPfC), we found that fibroblasts expressed higher levels of CSF1 than other cell types (Fig. 2.3,
A and B). In a human PDAC dataset (Peng et al., 2019) comprised of 21 PDAC samples,
fibroblasts also expressed a higher level of CSF1 than tumor cells and other cells within the TME
(Fig. 2.3, C and D). Others have also detected CSF1 in the cultures of primary CAFs from
PDAC patients (Samain et al., 2021). Collectively, these data suggest that fibroblasts are the
main producers of CSF1 in the PDAC TME. Next, we injected CSF1 IgG into mice bearing
orthotopic KP-2 tumors and measured macrophage proliferations 12 and 24 h after the injection.
Similar to the in vitro experiments, we found a significant reduction in the percentage of
macrophages undergoing proliferation, measured by BrdU incorporation (Fig. 2.3, E and F). We
have previously shown that sustained CSF1 depletion, exceeding 48 h, led to macrophage
depletion by apoptosis(Zhu et al., 2014). However, in this short period of treatment time, we did
not observe significant change in macrophage number (Fig. 2.3 G). Additionally, we found that
proliferation of monocytes was minimal and not significantly affected by aCSF1 IgG treatment
(Fig. 3 H), confirming that the reduction of proliferation was mainly from macrophages. Taken
together, these data suggest that CSF1 secreted by cancer-associated fibroblasts drives local
macrophage proliferation in pancreatic cancer.

The p21 cell cycle-dependent kinase inhibitor was induced in TAMs by CAF-derived CSF1.
We next asked whether the macrophage proliferation machinery regulated by CAFderived CSF1 could impact the TAM phenotype. We first examined the expressions of several
critical cell cycle regulators in BMDMs following treatment with either CSF1, the proliferative
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mitogen, or lipopolysaccharide (LPS), which is known to blunt macrophage proliferation (Liu et
al., 2016) (Fig. 2.10 A). We found that when BMDMs were treated with CSF1, overall protein
levels of c-Myc and cyclin D1 were upregulated while p27Kip1 was reduced (Fig. 2.4 A).
BMDMs treated with LPS showed the opposite result. These changes are consistent with the
existing roles of cell cycle promoters (c-Myc and cyclin D1) and a cell cycle inhibitor (p27Kip1)
(Liu et al., 2016; Matsushime et al., 1991). However, surprisingly, we found p21Waf/Cip1, a cell
cycle inhibitor (Cazzalini et al., 2010; Dutto et al., 2015; Brugarolas et al., 1999), was strongly
induced by both CSF1 and CAF co-culturing (Fig. 2.4, B and D). To further investigate this p21
induction, we performed a kinetic study of p21 expression in BMDMs and found that the p21
protein was induced by CSF1 within 6–12 h, which was prior to S phase entry at 24–48 h after
CSF1 administration, as measured by BrdU (Fig. 2.4, B and C). Similar kinetics and cell cycle
transit were found when BMDMs were cultured with fibroblasts in a Transwell assay (Fig. 2.4,
D and E). These data suggest that p21 induction by stoma-derived CSF1 could impact both
macrophage cell cycle and phenotype.
To test if p21 induction impacted macrophage phenotype, we knocked-down p21
expression in BMDMs by siRNA in the presence of CSF1. We found that p21 knockdown
resulted in a significant increase in the number of macrophages that entered S phase, confirming
p21’s inhibitory role in the G1/S transition (Fig. 2.10 B and C). To assess macrophage
phenotypic changes after p21 knockdown, we performed gene profiling analysis followed by
RT-qPCR validation of altered gene expressions. Transcription profiling revealed > 300 genes
that were differentially expressed in BMDMs upon p21 knockdown in the presence of tumor
conditioned medium (Fig. 2.4 F). Overrepresentation analysis of differentially expressed genes
demonstrated that p21 knockdown in BMDMs resulted in the upregulation of genes involved in

30

cell cycle progression, as expected, but also unexpectedly, it upregulated interferon  and 
responses (Fig. 4 G). RT-qPCR validation also found upregulation of interferon-related genes,
IFIT3, CD40, IFN- and IFN- Notably, gene expression of cyclins involved in early cell cycle
stage (G1), CCND1, CCNE, were unchanged, while CCNA, an S phase cyclin, was upregulated
(Fig. 4 H). Together, these data suggest that in addition to its canonical role in regulating S phase
entry, p21 might suppress interferon signaling pathways. In a CSF1-rich TME like PDAC,
elevated p21 expression in macrophages might play a prominent role in impairing tumor
immunity(Hervas-Stubbs et al., 2011).
Based on the significant presence of CSF1-producing CAFs in the PDAC TME, we
hypothesized that p21 might be chronically high in TAMs and thus might drive their immunesuppressive phenotype. We first evaluated p21 expression in human PDAC tumors by CyTOF
and found PDAC TAMs frequently expressed high levels of p21 (Fig. 2.4 I; Fig. 2.10 I).
Similarly, KPC tumors also had significant numbers of F4/80+ TAMs expressing high levels of
p21 evaluated by mpIHC (Fig. 2.10, H). Finally, ScRNAseq analysis suggested that TAMs from
both human and murine PDAC tissues had higher levels of p21 gene expressions than
macrophages in normal tissues (Fig. 2.4 J; Fig. 2.10 F). The elevation of p21 in PDAC tumors
could be a result of increased number of macrophages entering cell cycle as shown in Fig 2.1, H
and N. However, we observed in CyTOF, TAMs that were high in p21 expression, were not
necessarily high in the expression of PCNA or Ki67 (Fig. 2.4 I; Fig. 2.1 D), suggesting p21
expression was not only up in proliferating TAMs. In addition, we did not find a significant
difference in the p21 protein levels between Ki67+ vs. Ki67- TAMs by CyTOF, nor did we find
significant difference in p21 gene expression in proliferating and non-proliferating clusters of
TAMs in scRNAseq data (Fig. 2.10, D and G). Collectively, these results suggest that elevated
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p21 expression in PDAC TAMs is unlikely to be solely caused by cell cycle entry/progression, it
may become elevated by other factors in the TME and regulate TAMs phenotype.
To further assess the potential phenotypic differences in TAMs based on p21 expression,
we generated and analyzed data from four scRNAseq data sets, including one from human (Peng
et al., 2019)and three from PDAC mouse models(Hosein et al., 2019). We identified macrophage
populations in each mouse dataset and myeloid populations in human dataset based on known
macrophage markers after unsupervised clustering and UMAP projection (Fig. 2.9, F; Fig. 2.3 B
and D). We then stratified macrophages (myeloid cells in human) based on p21 gene expressions
to the p21High and p21Low grouped in each data set (Fig. 2.4 K). Notably, UMAP dimension
reduction revealed the similar spatial distributions of p21High and p21Low macrophages in tumors
from mouse GEMM and orthotopic models, suggesting shared characteristics among the same
group of TAMs in different models (Fig. S3 E). To understand what these common phenotypes
were, we performed Gene Set Enrichment Analysis between p21High and p21Low macrophages in
each dataset. Across all four datasets and both species, we found that hallmarks typically
associated with the tumor necrosis factor alpha (TNF-) signaling pathway, hypoxia, and
STAT5 signaling were upregulated in p21High macrophages, while oxidative phosphorylation
pathways were upregulated in p21Low macrophages (p21Low myeloid cells in human) (Fig. 2.4 L).
Although TNF- and its signaling pathway are proinflammatory, prolonged and irregulated
activation are frequently considered immunosuppressive in tumors. In this respect, TNF- can
mediate T cell exhaustion, CD8+ T cell death, and expansion of myeloid-derived suppressor cells
and regulatory T cells (TRegs) to promote tumor progression and metastasis (Salomon et al., 2018;
Balkwill, 2006). Consistent with the enrichment for TNF- via the NF-B signaling pathway,
expressions of IL-1, IL-1 and NF-B components were also upregulated in p21High
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macrophages (Fig. 2.4 M). Together, these data suggest that TAMs with high p21 expression
acquire an inflammatory but potentially immunosuppressive gene signature.
PDAC patients are frequently treated with cytotoxic chemotherapies, that can impact both
tumor cells as well as stromal cells. Therefore, we sought to next determine if chemotherapy
could

impact

TAM

proliferation

and

p21

expression

and

thus

influence

TAM-

immunosuppressive programs. First, we treated KPC GEMM with either modified FIRINOX (5FU, Irinotecan, and Oxaliplatin) or a combination of gemcitabine and paclitaxel (GEM/PTX).
Both chemotherapies are current frontline treatments for pancreatic cancer. We analyzed
p21HighF4/80+ TAMs 24 hours later by mpIHC and found that the number of p21High TAMs
significantly increased after both chemotherapy treatment (Fig. 2.4 N). To determine if this was
a direct effect of chemotherapeutic exposure, we treated BMDMs with four different
chemotherapeutics for 24 h and observed similar inductions of p21 (Fig. 2.4 O). Finally, to
assess if induction by of p21 might correlate with changes in macrophage phenotype induced by
chemotherapy, we analyzed TAMs from KPC GEMMs treated with vehicle or GEM/PTX by
scRNAseq. We found striking similarity in the pathways enriched in TAMs from mice treated
with GEM/PTX compared to vehicle and pathways found when we stratify TAMs in vehicle
treatment mice by p21 expression (Fig. 2.4 P). Similarly, TAMs from GEM/PTX treated KPC
mice showed higher expression of the p21High gene signature when compared to vehicle. (Fig.
2.10 K). These data suggested that p21 was induced by both stromal interaction and
chemotherapy treatments, and correlated with inflammatory and likely immunosuppressive
phenotypes in PDAC TAMs. Next we analyzed the p21High TAM signature in TCGA data sets
and found strong correlation with signatures of “T cell exhaustion”(Tirosh et al., 2016) and
“immune escape”(Lin et al., 2007) (Fig. 2.4 Q). Additionally, the p21 signature strongly
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correlated with CSF1 expression (Fig. 2.4 Q). These data suggest that stromal-CSF1 induced p21
expression in TAMs may drive dysfunctional T cell mediated tumor control.

Expression of p21 drove the tumor promoting phenotype in macrophages.
To better understand the impact of induction of p21 expression on the macrophage
phenotype, and on the PDAC TME, we engineered a mouse designed to constitutively express
p21 in myeloid cells. The construct contained the p21 gene under the control of a CAG promoter
and a lox-stop-lox case. Downstream of the p21 gene, the construct also contained an internal
ribosome entry site (IRES) and YFP gene for visualization. The construct was then integrated
into the ROSA locus of pure C57/B6 mice (ROSA-CAG-LSL-p21-IRES-YFP, p21+/wt) (Fig. 2.5
A). Then, p21+/wt mice were crossed with LysMCre mice to specifically induce p21 expression in
macrophages. The resulting LysM+/+/p21+/wt mice were termed “p21 constitutive expression”
(p21CE) mice.
To confirm that p21 expression was induced in macrophages from p21CE mice, we
measured p21 protein levels in BMDMs from p21CE mice in the presence and absence of CSF1.
We found BMDMs from p21CE mice expressed significantly higher levels of p21 protein in the
absence of CSF1 compared to control BMDMs (Fig. 2.5 B). However, in the presence of CSF1,
which strongly induced p21 expression in wildtype BMDMs (Fig. 2.4 A and B), both p21CE and
p21WT BMDMs had similar p21 expressions. These data indicated that macrophages from the
p21CE mouse model retained high p21 expression without stimuli and that the expression was at a
physiological level comparable to CSF1 exposure or fibroblast co-cultures.
Given LysMCre is known to be expressed in various myeloid compartments, including
granulocytes and monocytes(Abram et al., 2014), we next examined whether the hematopoietic
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system was altered in p21CE mice. Flow cytometry analysis of non-tumor-bearing p21CE mice
revealed that YFP, a surrogate for transgenic p21, was mainly expressed in mature monocytes,
macrophages, and granulocytes/neutrophils in the blood, bone marrow, spleen, and pancreas, but
minimally expressed in bone marrow progenitors and lymphocytes (Fig. 2.5 C). Corresponding
to the lack of expression in progenitor cells, we did not find major changes in the cellular
composition of bone marrow or blood in p21CE mice compared to controls, as assessed by flow
cytometry or by complete blood count analysis (Fig. 2.5 D; Fig. 2.11 A, B, and C). Taken
together, these data suggested that p21 was expressed in mature myeloid cells in p21CE mice, but
not in progenitors and it did not greatly impact hematopoiesis.
As shown above in the scRNAseq data and gene profiling analysis after p21 siRNA
knockdown, p21 expression regulated the macrophage phenotype. To assess whether
macrophages from p21CE mice had similar phenotypic changes, we profiled gene expressions of
BMDMs from p21WT, p21CE, and p21-/- (Jax mice) mice in the presence of CSF1. We found that
inflammatory cytokines/chemokines, CXCL1, CXCL2, IL-1, IL-1, IL-6, and TNF- were
upregulated in p21CE mice but reduced or not changed in p21-/- mice (Fig. 2.5 F). In addition, the
interferon regulatory factor 4 (IRF4)-mediated macrophage alternative activated genes, YM1 and
transforming growth factor beta (TGF-b), were also upregulated. In contrast, p21-/- BMDMs had
elevated levels of the interferon-related genes, IRF1, BATF, IFIT3 and CD40, which were
consistent with the changes in macrophages with siRNA-mediated knockdown of p21 (Fig. 2.5
F; Fig. 2.4 H). Consistent with upregulation of NF-B related genes, p21CE BMDMs in CSF1
withdraw condition showed elevated levels of total and phosphorylated p65, suggesting
enhanced NF-B activation (Fig. 2.5 E). Taken together, these data suggest that constitutive p21
expression regulates the macrophage phenotype and represses anti-tumor immunity.
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Next, we examined the impact of constitutive p21 expression in myeloid cells on PDAC
progression. We orthotopically implanted KP-2 cells into p21CE and p21WT mice and analyzed
tumors at the end point by flow cytometry. Similar to YFP expression patterns in non-tumorbearing mice, we found in PDAC tissues that the majority of TAMs, monocytes, and neutrophils
were YFP+ , but the vast majority of tumor infiltrating cDCs, lymphocytes, and bone marrow
progenitors were YFP- (Fig. 2.5 G). Corresponding to lack of expression in DCs, we found no
major changes in the numbers of cDC1s and cDC2s in pancreatic tissues from p21CE tumorbearing mice (Fig. 2.11 E). Additionally, the number of other myeloid cells that were not largely
dependent on proliferation was also not changed in p21CE when compared to p21WT (Fig. 2.11
E). With constitutive expression of p21, we found a reduction in TAM proliferation, as measured
by BrdU, as well as a decrease in total TAM numbers (Fig. 2.5 H and I). These data suggest that
local proliferation of TAMs is necessary to sustain a local TAM pool. Interestingly, while TAM
depletion in other studies typically slowed tumor growth(Zhu et al., 2014; Borgoni et al., 2018;
Candido et al., 2018), we saw a significant increase in tumor burden in p21CE mice (Fig. 5 J).
These data suggest that changes in myeloid phenotype mediated by p21 drives tumor
progression. Before evaluating the phenotypic changes of TAMs in p21CE mice, we examined the
tumor promoting effects on other tumor models. Similar to orthotopic KP-2, the PDA.69 PDAC
model(Lee et al., 2016) and PyMT mammary tumor model showed decreased TAM
proliferations and numbers, but accelerated tumor progression (Fig. 5, K and L). Together, these
data suggest that constitutive expression of p21 in myeloid cells reduces TAM proliferations and
numbers, but also alters TAM phenotype to drive tumor progression.
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The p21 expression in macrophages led to an inflammatory but immunosuppressive
phenotype.
We next sought to explore how high p21 expression in myeloid cells affected their
phenotype in vivo. We conducted scRNAseq analyses on sorted CD45+ cells from PDAC tissues
in p21WT and p21CE mice. An unsupervised clustering algorithm identified 19 clusters (Fig. 2.12
A), which mainly included C1qa-expressing macrophages, Ly6C2-expressing monocytes,
S100a8-expressing granulocytes, Cd3d-expressing T cells, and Ms4a1-expressing B cells (Fig.
2.6 A; Fig. 2.12 B). To assess transgene expression, we analyzed the expression of YFP
sequences. Consistent with flow cytometry data, myeloid compartments, including macrophages,
monocytes, neutrophils, and eosinophils had high YFP expressions, while DCs had minimal and
non-myeloid cells had no expression (Fig. 2.6 B).
To more accurately define myeloid subpopulations identified by scRNAseq and evaluate
the phenotypic changes in each, starting from TAMs, we computationally separated
macrophage/monocyte clusters and reanalyzed these at a higher resolution. This approach
generated 17 clusters, which were grouped into four major populations, including macrophages
with high MHCII expression (MHCIIhi Macs), low MHCII expression (MHCIIlow Macs),
monocytes (Mono, Mono2), and proliferating macrophages (ProMacs) (Fig. 2.6 C). After
identifying major macrophage subsets, we first performed cell cycle analysis on all macrophages
and confirmed that their proliferations were reduced (Fig. 2.6 D). Second, we observed that a
higher percentage of TAMs in p21CE was in the MHCIllow cluster, and that this change was also
observed at the protein level by flow cytometry (Fig. 2.6, E and F), indicating that TAMs in
p21CE potentially had impaired cross-presentation. Third, we performed Gene Set Enrichment
Analysis (GSEA) between p21CE TAMs and p21WT TAMs and found that consistent with in vitro
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experiments, TAMs in p21CE were enriched in TNF- signaling, as well as pathways associated
with hypoxia and inflammatory responses (Fig. 2.6 H; Fig. 2.13 A). Notably, we also observed
downregulation of genes associated with antigen processing and presentation of H2-Aa, H2-Ab1,
H2-Eb1, and Cd74, and with the complement components of C1qa, C1qb, and Lyz, whereas
tissue remodeling markers of Arg1, Mmp19, Vegfa, and Mmp9 were upregulated in TAMs from
p21CE tumor-bearing mice (> 1.5-fold, adjusted p < 0.05) (Fig. 2.6 I). Taken together, these data
suggest that TAMs in p21CE are more inflammatory, characterized by high TNF- signaling, and
are more immunosuppressive, characterized by both impaired anti-tumor functions and
expressions of M2-like gene signatures. In addition, we found an increase of eosinophils within
the TME of PDAC from p21CE tumor-bearing mice (Fig. 2.12 C), which further illustrated that
the TME was more inflammatory.
To further confirm that the p21CE model recapitulated the characteristics of p21High TAMs
identified in mouse PDAC tissues in Fig. 2.4 L, we examined the expression levels of p21High
gene signature defined in Fig. 2.4 M in TAMs from p21CE and p21WT tumor-bearing mice. We
found that TAMs in p21CE expressed significantly higher levels of the p21High gene signatures
(Fig. 2.12 D). In addition, a gene encoded for the common  chain of the FC receptor (Fcer1g)
was significantly reduced in p21High TAMs across three mouse scRNAseq datasets in Fig. 4 M.
Cross-linking of FcRs and the common  chain is required for IgG-mediated response and
phagocytosis(Castro-Dopico and Clatworthy, 2019). Therefore, we evaluated whether p21CE
macrophages had impaired FcR-mediated phagocytosis. We cultured BMDMs differentiated in
medium containing CSF1 from p21CE or p21WT non-tumor-bearing mice with IgG-coated beads
and found significantly less phagocytosis in p21CE BMDMs (Fig. 2.6 G). These data suggest
TAMs with high p21 expression have impaired effector functions which could contribute to
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tumor progression. Finally, we analyzed a gene expression signature derived from TAMs in
p21CE mice in human PDAC expression datasets. Our analysis found that the p21CE signature
was also associated with “immune escape” signatures(Lin et al., 2007) and poor progression free
survival (Fig. 2.6 J and K).
To understand the changes in other myeloid cells from p21CE mice, we compared the
numbers of significantly changed genes in each myeloid population between the two genotypes.
We found that TAMs showed the largest number of differentially expressed genes (DEGs) (80
genes), followed by monocytes (34 genes), and only a few genes in neutrophils and granulocytes
(Fig. 2.12 G). These data suggest macrophages are likely the predominant driver of tumor
burden differences. To confirm macrophages contribution to the tumor acceleration in p21CE
mice, we administered CSF1 IgG and clodronate-containing liposomes to p21CE and p21WT
tumor-bearing mice throughout tumor development. We found that the number of TAMs was
significantly reduced, while the number of other CD45+CD11b+F4/80- myeloid cells did not after
the treatment in both genotypes of mice (Fig. 2.12, I and J). Only in the setting of macrophage
depletion were the tumor promoting effects observed in p21CE mice abolished (Fig. 2.12 H).
Therefore, these data suggest that macrophages are the main driver for tumor acceleration in
p21CE mice.
Although YFP was not significantly expressed by DCs, DCs play a critical role in antigen
processing and presentation as well as CD8+ T cell activity and could potentially affect tumor
progression(Gardner and Ruffell, 2016). To evaluate the changes in DCs in p21CE tumors, we
reclustered DC populations from scRNAseq data at a higher resolution and identified seven
major subsets: cDC1, cDC2a, cDC2b, migratory DC (MigDC), pDC, and proliferating cDC1 and
cDC2 (Fig. 2.12 E). The cDC1 expressed classical DC1 markers of Xcr1, Clec9a, and also Baft3
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and Irf8, while the cDC2 subsets expressed Cd11b, Irf4, and Sirpa, and were further separated
into cDC2a and cDC2b based on Epcam expression(Merad et al., 2013; Kaplan, 2017). We did
not observe significant changes in the percentages of cDC1s, cDC2s, migratory DCs, and
proliferating DCs as the total number of DCs between two genotypes, nor did we observe a
change in genes associated with cross-presentation. We saw a decrease in pDCs and an increase
of cDC2bs as the percentage of total DCs (Fig. 2.12 F). Because pDCs are one of the major
producers of type-I interferon(Koucký et al., 2019) and could potentially drive anti-tumor
immunity, this reduction could impact tumor immune suppression.

The p21 expression in macrophages impaired effector T cells.
To determine if impaired antigen processing and presentation in macrophages directly
affected T cell numbers and functions, we reanalyzed T cell clusters from the scRNAseq
experiment at a higher resolution. Unsupervised clustering generated 12 clusters and were
manually assigned into natural killer cells (NK cells), regulatory T cells (TRegs), two clusters of
CD4+ (CD4#1 and CD4#2), two clusters of CD8+ (CD8#1 and CD8#2), double negative T cells
(DNs), and a gamma delta T cell based on known cell type markers (Fig. 2.7 A). Among CD8+ T
cells, cluster #2 expressed the higher effector genes, Gzma, Gzmb, and Cd74, and therefore was
considered as cytotoxic effectors (Fig. 2.7 A). We observed that this CD8+ effector cluster was
reduced as a percentage in p21CE tumor-bearing mice (Fig. 2.7 B) and the expressions of effector
genes, Gzma, Gzmk, Klrg1, were also significantly lower (Fig. 2.7 D). In contrast, we saw an
increase in the percentage of CD4#2 T cell populations, which are TH2 polarized, with high
levels of Gata3, IL-4 and IL-13 (Fig. 2.7 B)(Zheng and Flavell, 1997). If mapping the
upregulated genes in cytotoxic CD8+ T cells from p21CE tumors to known signaling pathways,
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we found enrichment in apoptosis and IL-2-STAT5 signaling, suggesting overexpressed p21 in
macrophages may cause more cytotoxic CD8+ T cell death (Fig. 2.7 C). To confirm this, we cocultured CD3/CD28 beads activated CD8+ T cells with BMDMs generated from p21CE and
p21WT mice in vitro, and found p21CE BMDMs led to more 7AAD+ CD8+ T cells (Fig. 2.7 E). To
extend the findings to human PDAC patients, we analyzed the correlations between the p21CE
signature in TAMs with “T cell exhaustion”(Tirosh et al., 2016) and found strong positive
correlations (Fig. 2.7 L). Taken together, these data suggest high p21 expression in TAMs
dampens cytotoxic CD8+ T cell mediated tumor control.
To

corroborate

these

findings,

we

used

a

T

cell-focused

CyTOF

panel.

CD45+TCRb+CD90+NK1.1-TCR-T- cells were selected for further clustering based on 20 T
cell functional markers. This approach generated 18 clusters that could be mainly grouped into
three major populations: CD4+ T cells, regulatory CD4+ T cells (TRegs), and CD8+ T cells (Fig.
2.7, F and G). We next evaluated changes in each subpopulation and found a significant
decrease in the numbers of cytotoxic effectors (cluster 4), which expressed high levels of
granzyme B and KLRG1. In addition, we observed an expansion of the CD4+Treg (cluster 5) that
expressed high levels of PD1 (Fig. 2.7 H). In addition, we found that CD8+ T cells as a whole in
p21CE tumors expressed lower levels of KLRG1 and CD90, but higher levels of CD44, Tim3,
and PD1, indicating a more exhausted and less functional phenotype (Fig. 2.7 I). We further
confirmed that in p21CE tumors, significant less CD8+ T cells express TNF- and IFN compared to in p21WT tumors (Fig. 2.7 J). Finally, to determine whether accelerated tumor
progression in p21CE mice was driven by T cells, we depleted CD8+ T cells in both p21CE and
p21WT mice through injection of CD8 IgG. We no longer observed difference in tumor burdens
between the two groups (Fig. 2.7 K). These data suggest that p21-driven TAM
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immunosuppressive phenotype not only reduces the number of anti-tumor T cells but also
impairs the functions of remaining T cells.
As we saw increased expression of CD40 in TAMs from both GEMM KPC and
orthotopic models (Fig. 2.8 A), we next asked whether innate immune agonist therapy, CD40
agonist, could reeducate TAMs and restore their effector functions(Coveler et al., 2020). To test
this, we treated p21CE and p21WT mice bearing orthotopic KP-2 tumors with CD40 agonist plus
gemcitabine and found that while the dual treatment had limited effect on p21WT mice, it
dramatically reduced the tumor burden in p21CE mice and increased CD8+ T cell infiltration (Fig.
2.8 B, C). These data suggest, although stromal or chemo-induced p21 expression drives an
inflammatory and immunosuppressive phenotype in TAMs, these same pathways may make
tumor uniquely susceptible to CD40 agonist therapy.
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2.3 Figures:
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Figure 2.1
Pancreatic

ductal

adenocarcinoma

(PDAC)-infiltrating

macrophages

are

highly

proliferative. (A) Representative immunohistochemistry (IHC) analyses of CD68+ macrophages
and CK19+ tumor cells in the late stage of PDAC tissues and adjacent normal tissues from
human patients. (B) Representative IHC analyses of F4/80+ macrophage and CK19+ tumor cells
in normal pancreas, early, mid and late stages of KPC genetically engineered mouse models
(GEMMs). (C) Quantification of F4/80+ cells per millimeter of measured tissue area in B. (D)
Representative tSNE plots of total normalized CD45+ cells from a PDAC patient, annotated with
manually assigned cell identity. The macrophage cluster was marked with a red circle, and
expressions of PCNA and Ki67 were explicitly displayed. (E,F) Dot plot displaying
quantification of tumor-associated macrophages (TAMs), Ki67+ TAMs, and Ki67+ neutrophils
across nine human PDAC patients. (G) UMAP of realigned and reprocessed publicly available
human pancreatic ductal adenocarcinoma (PDAC) dataset (Peng et al., 2019), displaying major
CD45+ clusters with expression levels of MKi67 and a heat map showing key gene expressions
for each cluster. n = 21 PDAC samples, n = 6 normal samples. (H) UMAP plots displaying
normalized expression levels of MKI67 across subpopulations with red arrow pointing to MKI67
expressing myeloid cells. (I, J) Representative multiplex immunohistochemistry (mpIHC)
displaying F4/80+ macrophages, CK19+ tumor cells, and Ki67+ proliferating cells in tumors from
p48-Cre+/LSL-KrasG12D/p53flox/flox (KPC) GEMMs with quantification of Ki67+ macrophages; n =
6 mice. (K, L) Quantification of total TAMs as per gram of tumor and percentage of cells, 5bromo-2'-deoxyuridine (BrdU) incorporation of TAMs in orthotopic tumors from two PDAC cell
lines. (M) UMAP displaying proliferating macrophages and non-proliferating macrophage
clusters across the mouse scRNAseq data set used in J with quantification in (N). Data are
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presented as the mean ± SEM. n.s., not significant; *p < 0.05. For comparisons between any two
groups, Student’s two-tailed t-test was used.
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Figure 2.2
Fibroblasts drive macrophage proliferation through colony stimulating factor-1 (CSF1).
(A) Representative multiplex immunohistochemistry (mpIHC) image of p48-Cre+/LSLKrasG12D/p53flox/flox (KPC) mouse pancreatic ductal adenocarcinomas (PDACs) displaying alpha
smooth muscle actin (αSMA+) (white) fibroblasts, CK19+ (teal) tumor cells, and F4/80+ (green)
macrophages. (B) Frequency distribution of Pdpn+ fibroblasts (blue curve) and CK19+ tumor
cells (green curve) to a nearest F4/80+ macrophage. n = 6 KPC mice. (C) The 5-bromo-2'deoxyuridine (BrdU) incorporation and number of bone marrow-derived macrophages
(BMDMs) in co-culture with KP-1, KP-2, fibroblasts, or the combination for 48 h, BrdU pulsed
for the last 6 h; n = 6. (D) The BrdU incorporation of BMDMs when cultured with fibroblasts in
a Transwell assay or 10 ng/mL of CSF1 for 48 h, and BrdU pulsed for the last 6 h; n=3. (E)
Representative image of a cytokine antibody array resulting from fibroblast- and KP-2conditioned media, highlighting the top 10 highly expressed cytokines in fibroblast-conditioned
medium and the corresponding mean pixel densities. The arrays were repeated two times. (F)
Bar graph shows the concentrations of CSF1 from three tumor-conditioned media (KP-1, KP-2,
and KI) and fibroblast-conditioned medium measured by an ELISA. (G) BrdU incorporation of
BMDMs in co-culture with fibroblasts treated with 2 µg of aCSF1 or 2 µg of aIgG for 24 h, and
BrdU pulsed for the last 6 h; n=3. (H,I) BrdU incorporation and number of BMDMs in
Transwell cultures with fibroblasts with or without siRNA knockdown for CSF1; n=3. Data are
presented as the mean ± SEM. n.s., not significant; *p<0.05. All in vitro assays were consistent
across at least two independent repeats. For comparisons between any two groups, Student’s
two-tailed t-test was used. Frequency distributions were compared using the nonparametric
Kolmogorov-Smirnov test.
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Figure 2.3
Cancer-associated fibroblasts drive tumor associated macrophage proliferation through
colony stimulating factor-1 (CSF1). (A) Dot plot summarizing CSF1 expressions in different
cell types across three mouse PDAC models from the publicly available scRNAseq dataset
(Hosein et al., 2019). (B) UMAP dimensionality reduction plot of integrated cells from LKIC,
LKP R172H/+C, and LKPFC genetically engineered mouse models in scRNAseq dataset used in A,
annotated with different cell types. Data were filtered and reprocessed as described in the
Methods. (C) Dot plot displaying CSF1 expressions in different cell types across 21 human
PDAC patient samples from the publicly available scRNAseq dataset(Peng et al., 2019). (D)
UMAP dimensionality reduction plot of integrated cells from 21 pancreatic adenocarcinoma
patients used in C, annotated with different cell types. (E-H) Representative flow cytometry plot
and quantification bar plot showing BrdU+ macrophages and monocytes, and total number of
macrophages following IgG or CSF1 injections; n = 6-8 mice per group. Data are presented as
the mean ± SEM. n.s., not significant; *p<0.05. For comparisons between any two groups,
Student’s two-tailed t-test was used.
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Figure 2.4
The p21 cell cycle-dependent kinase inhibitor is induced by CSF1 and regulates the
macrophage phenotype. (A) Immunoblots of p21, p27, c-Myc, and cyclinD1 in bone marrowderived macrophages (BMDMs) after treatment with 100 ng/mL of lipopolysaccharide or colony
stimulating factor-1 (CSF1) for 24 h. The experiments were repeated three times. (B)
Immunoblot displaying p21 expression in BMDMs following 4 ng/mL CSF1 treatment at time 0
with quantification of BrdU+ BMDMs shown in (C), 5-bromo-2'-deoxyuridine (BrdU) was added
at time 0 and pulsed until harvest. BMDMs were starved without CSF1 overnight. (D)
Immunoblot displaying p21 expression in BMDMs combined with fibroblasts in Transwell
assays at time 0. (E) Bar plot displaying the quantification of BrdU+ BMDMs in D. (F) Heat map
displaying the microarray analysis of differentially expressed genes (DEGs) between non-target
siRNA treated or siRNA targeting for p21 treated BMDMs cultured in tumor-conditioned
medium for 24 h; n = 3 per group. Genes were filtered with adjusted p < 0.05 and fold-change >
or < 1.5. (G) Bar graph displaying top overrepresentation analysis of DEGs in F to known
biological functions [Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes
(KEGG), REACTOME, and Molecular Signatures Database (MSigDB)] with a false discovery
rate (FDR) < 0.05. (H) Heat map displaying qPCR analysis of gene expressions of cell cycle and
interferon-related genes between non-target siRNA treated or siRNA targeting for p21 treated
BMDMs cultured in tumor-conditioned medium for 24 h; fold-change > 1.5, n = 3/group of the
comparison. (I) Representative tSNE plot displaying major cell types from CyTOF analysis of a
human PDAC patient (same as in Fig. 2.1 D) with macrophages circled in red and p21
expression. (J) UMAP displaying CDKN1A gene expression in CD45+ cells from the human
PDAC scRNAseq dataset (Peng et al., 2019) with annotation of key cell types. (K) Violin plot
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showing the expression levels for p21 gene in macrophage clusters from integrated scRNAseq
analyses of the mouse normal pancreas and pancreatic tissue from KPC GEMMs and orthotopic
KP-2 tumor-bearing mice. Representative lines were drawn for two groups of stratified
macrophages based on the top 10% of p21 expression and bottom 10% of p21 expression. (L)
Heat map of net enrichment score (NES) of shared enriched pathways identified by GSEA
analysis comparing the two groups of macrophages (p21High vs. p21Low) in human PDAC
scRNAseq dataset (23), (27), KPC GEMM and orthotopic scRNAseq data. Enriched pathways
were selected by FDR < 0.01. (M) Heat map displaying the shared DEGs when comparing
p21High to p21Low tumor-associated macrophages (TAMs) in each dataset with adjusted p < 0.05
and fold-change > 1.2 or < 0.8. p21High signature score was created utilizing filtered DEGs with
fold-change > 1.5 across three mouse scRNAseq datasets. (N) Representative mpIHC image
displaying F4/80+ TAMs, CK19+ tumor cells, and p21+ cells in KPC GEMM treated with
dimethyl sulfoxide or FOLFIRINOX for 24 h with quantification of p21+TAMs as total cells and
total TAMs on the right. (O) Immunoblots showing expressions of p21 in BMDMs after
treatment with chemotherapeutics for 24 h. (P) Heat map of NES of shared enriched pathways
identified by GSEA analysis in comparing p21High to p21Low TAMs in KPC GEMM PDAC and
in comparing chemotherapeutic treated KPC GEMM PDAC to DMSO treated KPC GEMM
PDAC with FDR < 0.05. (Q) Correlation plots with Pearson coefficients (r) of p21 signature
score vs. T cell exhaustion score (Tirosh et al., 2016), Immune escape score (Lin et al., 2007),
and CSF1 expression from TCGA PDAC PanCancer Atlas study (n=180).
All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05. All in vitro assays
and immunoblots were consistent across more than two independent repeats. For comparisons
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between any two groups, Student’s two-tailed t-test was used, except for F, M where the
Bonferroni correction was used and for L, P where the FDR was used.
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Figure 2.5
Expression of p21 drives tumor promoting phenotypes in macrophages. (A) Genetic loci for
the p21CE model. (B) Immunoblot for p21 expression in p21CE or B6-derived bone marrowderived macrophages (BMDMs) with or without 10ng/ml of colony stimulating factor-1 (CSF1)
treatment for 24 h. Experiments were consistent in two independent repeats. (C) Bar plot
displaying the percentage of YFP+ cells in non-tumor-bearing p21CE mice; n = 4. (D) Bar plot
showing flow cytometry quantification of cellular composition in non-tumor-bearing bone
marrow from p21CE and p21WT mice; n = 6–9 mice/group. (E) Immunoblot for phos-p65, total
p65, IKb, and p21 expression in p21CE or p21WT BMDMs withdrawed CSF1 for 24 hours. (F)
Heat map displaying gene expression analysis of BMDMs derived from non-tumor-bearing
p21WT, p21-/-, and p21CE mice treated with 10ng/ml of CSF1 for 24 h, by RT-qPCR; n = 3/group,
data was consistent from three independent repeats. (G) Flow cytometry quantification of YFP+
cells in p21CE mice bearing orthotopic KP-2 tumors; n = 6–7 mice. (H,I) Quantification of BrdU+
macrophages and density of macrophages in tumors of p21CE and p21WT mice; n = 6–7
mice/group. Data were pooled across multiple independent experiments. (J) Bar plot displaying
the tumor sizes in p21CE and p21WT mice, 21–27 days following orthotopic implantation of KP-2
tumor cells; n = 8–10 mice/group. Data were pooled from multiple independent experiments. (K)
Bar plot displaying tumor sizes, density of macrophages, and quantification of BrdU+
macrophages from p21CE and p21WT mice, 21–23 days after the orthotopic implantation of the
PDA.69 cell line; n = 8–10 mice/group. Data were pooled from multiple independent
experiments. (L) Caliper measurement of orthotopic PyMT in p21WT and p21CE mice; n = 6–8
mice /group. All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05. All in
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vitro assays were consistent across more than two dependent repeats. For comparisons between
any two groups, Student’s two-tailed t-test was used.
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Figure 2.6
The p21 expression in macrophages led to an inflammatory but immunosuppressive
phenotype. (A) UMAP dimensionality reduction plot of total CD45+ cells from p21WT and p21CE
mice bearing orthotopic KP-2 tumors. Cells in each genotype were pooled from three mice and
created as two libraries. Clusters were annotated with corresponding cell types. (B) Dot plot
displaying YFP expression in each cell type between the two groups. The legend shows the dot
size and corresponding percentage that are expressed as a color gradient of normalized
expressions. (C) Reclustered UMAP plot of macrophage and monocyte clusters in A without cell
cycle regression and split into p21WT and p21CE, and annotated with major subpopulations. on the
right, heat map showing key gene expressions in each subpopulation in C. (D) Pie chart showing
cell cycle analysis of macrophages (MHCIIhi, MHCIIlow, and ProMac) in tumors from p21WT and
p21CE mice. (E) Bar plot showing quantification of each population between p21WT and p21CE
mice identified in C. (F) Quantification of flow cytometry analysis of the percentages of
MHCIIhi and MHCIIlow macrophages from p21CE and p21WT mice bearing orthotopic KP-2
tumors with the representative gating strategy; n = 6–10 mice/group. Data were consistent in four
independent repeats. (G) Barplot displaying quantification of fluorescent-bead+ bone marrowderived macrophages from p21WT and p21CE mice. Data were consistent in three independent
repeats. (H) Bar plot displaying Gene Set Enrichment Analysis results of comparing tumorassociated macrophages (TAMs) from p21CE to p21WT mice. The key upregulated and
downregulated pathways are shown with a false discovery rate < 0.01. (I) Heat map showing the
key differentially expressed genes (DEGs) comparing TAMs from p21CE and p21WT mice. DEGs
were filtered with an adjusted p < 0.05 and fold-change > 1.3 or < 0.75. All gene expressions
were normalized by SCTransform. (J) Correlation plots with Pearson coefficients (r) of p21CE
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signature score (included genes with LogFC >0.75) vs. Immune escape score from TCGA PDAC
PanCancer Atlas study (n=180). (K) Kaplan-Meier survival analysis of PDA patients from
TCGA whose samples were stratified by expression of the p21CE signature (LogFC >0.75) by
quartiles. All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05 using the
t-test, except for I where the Bonferroni-corrected adjusted p-value was used.
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Figure 2.7
The p21 expression in macrophages impaired effector T cells. (A) UMAP dimensionality
reduction plot of selected lymphocytes (clusters 6, 7, 8, 13, and 17 in Fig. S4, A and B) from
p21WT and p21CE orthotopic KP-2 tumors. Clusters were annotated with corresponding cell types
and heat maps displaying selected gene expressions in each cell type. (B) Bar graph displaying
the composition of each cell type as the percentage of total CD45+ cells in p21WT and p21CE
tumor-bearing mice. CD8#2 and CD4#2 are highlighted with red arrows. (C) Bar graph
displaying the upregulated pathways in the CD8#2 cluster from p21CE using overrepresentation
analysis of differentially-expressed genes (DEGs) to known biological functions (Gene
Ontology, Kyoto Encyclopedia of Genes and Genomes, REACTOME, and the Molecular Signal
Database). DEGs were filtered with a value of p < 0.05, fold-change > 1.2, and past MAST test.
(D) Table showing the differentially expressed genes comparing CD8#2 cluster from p21CE to
p21WT with p.value < 0.05. (E) Bar plot displaying the percentage of 7-AAD+CD8+ T cells
activated with CD3/CD28 Dynabeads (Gibco) when cocultured with BMDMs from p21CE and
p21WT mice for 48 h. Data were consistent in three independent repeats. (F) UMAP plot of
selected CD45+TCRb+CD90+NK1.1-TCR-gdT- cells from p21CE and p21WT orthotopic KP-2
tumors with clusters annotated; n = 7 mice/group. (G) Heat map displaying the feature
expressions in each cluster. Cytotoxic T cells (cluster 4) and PD1High Treg (cluster 5) were
highlighted. (H) Bar plot showing the percentages of cytotoxic T cells and PD1High Treg in p21WT
and p21CE tumors. (I) Violin plot visualizing the expression levels of CD90, CD44, KLRG1,
TIM3, and PD1 in the CD8 cluster between tumors from two genotypes. (J) Bar graph
displaying the percentage of IFNgTNFa+ effector CD8 T cells in p21WT and p21CE tumors. (K)
Bar graphs showing the tumor burden, macrophages as the percentage of total cells, or as per
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gram of tissue, and the percentage of BrdU+ macrophages between p21WT and p21CE orthotopic
KP-2 tumors after aCD4/CD8 treatment; n = 6-8 mice/group. (L) Correlation plots with Pearson
coefficients (r) of p21CE score vs. T cell exhaustion score from TCGA PDAC PanCancer Atlas
study (n=180). All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05 for
comparisons between two groups E,H,I,J,K, Student’s two-tailed t-test was used. For
comparisons in I, the Bonferroni-corrected p-value was used.
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Figure 2.8
The p21 expression in macrophages sensitize tumors for innate immunotherapy. (A) Dot
plot showing average expression of CD40 in macrophages from normal pancreas and in TAMs
from KPC tumors. Dot size representing the percent of cells expressing CD40. (B) Bar graph
showing the tumor burdens of p21WT and p21CE mice bearing orthotopic KP-2 tumors with or
without CD40 agonist and gemcitabine treatment. n= 6-8 mice/group. Data were consistent in
two independent repeats. (C) Bar graphs showing the MFI of CD40 and MHCI in TAMs and
percentage of CD8 as of total cells from p21WT and p21CE mice bearing orthotopic KP-2 tumors.
All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05 for comparisons
between two groups, Student’s two-tailed t-test was used.

64

65

Figure 2.9
(A) Representative flow cytometry plots showing the gating strategy to identify macrophages,
monocytes, neutrophils, and eosinophil in orthotopic KP-2, KPC tumors. (B) Bargraph
displaying percentage of Ki67+ cells in TAMs, monocytes, neutrophils, and Eosinophils. (C)
Representative tSNE plots of human pancreatic adenocarcinoma (PDAC) samples, displaying
markers used for identifying major cell types, CD56+ for natural killer cells, CD19+CD3+ for T
cells, CD16+ for neutrophils, CD68+CD64+CD14+ for macrophages, CD1c+ for cDC2, and
CD141+ for cDC1 cells; n = 9 PDAC patients. (D) Representative Ki67+ gating in macrophage
and neutrophil clusters. (E) Schematic of the scRNAseq analysis pipeline. Details of each step
for the specific dataset are listed in Methods. (F) UMAP dimensionality reduction plot of
integrated sorted CD45+ cells from the murine normal pancreas and pancreatic tissues from KPC
PDACs and KP-2 orthotopic PDACs with cell type annotations and cell cycle regression. (G)
UMAP plot of reclustered macrophages/monocytes in F without cell cycle regression with a heat
map displaying corresponding gene signatures.
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Figure 2.10
(A) Dot plot displaying the percentage of Ki67+ macrophages in bone marrow-derived
macrophages (BMDMs) after colony stimulating factor-1 (CSF1) or lipopolysaccharide
treatment for 24 h; n = 3/group. (B) Immunoblot showing expression of p21 in BMDMs after
treatment with non-targeting siRNA or siRNA targeting for p21 in the presence of CSF1 for 24
h. Experiments were repeated in more than three independent repeats, and included tumor
conditioned-medium (TCM) treatment or were cultured with fibroblasts in Transwell assays. (C)
Bar plot displaying quantification of BrdU+ BMDMs in B. The 5-bromo-2'-deoxyuridine (BrdU)
was pulsed for 20 h. The experiments were repeated three times with three different siRNA
oligonucleotides. (D) Bar plot showing the expression levels of p21 in Ki67+ and Ki67- tumorassociated macrophages (TAMs) identified in Fig. S1 C; n = 9. (E) UMAP displaying p21High
and p21Low macrophages in p48-Cre+/LSL-KrasG12D/p53flox/flox (KPC) pancreatic ductal
adenocarcinoma (PDAC) tumors and orthotopic KP-2 tumors. (F) Dot plot showing Cdkn1a
(p21) gene expressions in the normal pancreas and pancreatic tissue from EKIC, LKIC, LKPC,
and LKPFC genetically engineered mouse models (Hosein et al., 2019). (G) Violin plot of the
expressions of p21 and Ccnb1 in non-proliferating and proliferating macrophages in the mouse
scRNAseq dataset from the KPC, orthotopic KP-2, and normal pancreas in Fig. 2.1 L. (H)
Representative image of multiplex immunochemistry (mpIHC) for F4/80+ macrophages, CK19+
tumor cells, and p21+ cells with quantification of p21+ macrophages from KPC PDACs; n = 8.
(I) Bargraph showing percentage of p21+ in different immune populations from human PDAC
tumors identified in Figure 2.1 D. (J) Representative mpIHC images of KPC mouse PDACs
displaying p21, CK19, F4/80, and Pdpn staining; n = 8. (K) Violin plot displaying the
expressions of p21High signature scores, identified in Fig. 2.4 M, in tumor-associated
macrophages from KPC mice 24 h after gemcitabine and paclitaxel (GEM/PTX) or dimethyl
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sulfoxide treatment. All graphs are expressed as the mean ± SEM. n.s., not significant; *p < 0.05.
All in vitro assays were consistent across more than two independent repeats. For comparisons
between any two groups, Student’s two-tailed t-test was used, except for K where the
Bonferroni-corrected adjusted p-value was used.
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Figure 2.11
(A) Quantification of white blood cells, red blood cells, and platelets in non-tumor-bearing
p21WT and p21CE mice at weeks 8 and 12; n = 3–4 mice/group. (B) Flow cytometry
quantification of total monocytes, neutrophils, and Ly6Chi monocytes in blood of non-tumorbearing p21WT and p21CE mice; n = 7–9 mice/group. (C) Flow cytometry quantification of
monocytes, neutrophils, and macrophages in the spleens of 8–12 weeks p21WT and p21CE nontumor-bearing mice; n = 7–9 mice/group. (D-F) Flow cytometry quantification of myeloid cells
in bone marrow and blood of tumor-bearing p21CE and p21WT mice ; n = 6 mice/group. (E) Flow
cytometry analysis of the number of monocytes, neutrophils, cDC2s, cDC1s, NK cells, NKT
cells and Tcell in the pancreas of p21CE and p21WT mice bearing orthotopic KP-2 tumors; n = 6
mice/group. (E) (F) Flow cytometry quantification of myeloid cells in the blood of tumorbearing p21CE and p21WT mice; n = 6 mice/group. All graphs are expressed as the mean ± SEM.
n.s., not significant; *p < 0.05. For comparisons between any two groups, the Student’s twotailed t-test was used.
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Figure 2.12
(A) UMAP plot of all sorted CD45+ cell clusters on merged objects from p21CE and p21WT KP-2
orthotopic tumor-bearing mice. Three mice were pooled for each genotype. (B) Heat map listing
all clusters in A and corresponding cell type annotations and key gene expressions. (C) Bar plot
displaying the percentages of neutrophils and eosinophils in p21WT and p21CE tumor-bearing
mice. (D) Violin plot displaying the expression levels of p21High signature scores, identified in
Fig. 2.4 M, in TAMs from p21CE and p21WT mice. *Wilcox adjusted p.value < 0.05. (E) UMAP
plot of the reclustered DC populations in Fig. 2.6 A, annotated with cell type and associated key
gene expressions in the heat map (right). (F) Quantification of major DC populations identified
in D from p21CE tumors when compared with p21WT tumors. (G) Heat map showing the number
of shared differentially-expressed genes (DEGs) between two genotypes in each cell population,
including macrophage and close lineages. The number of DEGs for each single cell population
when comparing p21CE to p21WT was listed in the parenthesis below. (H-J) Bar plot showing the
tumor burden, percentages of tumor-associated macrophages and monocytes in p21WT and p21CE
mice bearing orthotopic KP-2 tumors with or without colony stimulating factor-1 and clodronate
treatment; n = 8–10 mice/group. n.s., not significant; *p < 0.05. For comparisons between any
two groups, the Student’s two-tailed t-test was used.
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Figure 2.13
(A) Bar plot showing significantly upregulated and downregulated pathways identified by GSEA
in tumor-associated macrophages from p21CE compared with p21WT mice. The pathways were
grouped into biological functions with a false discovery rate < 0.01.
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2.4 Tables:
Table 2.1: Array top regulated genes sip21 vs. siNT; n = 3 each.
Top downregulated genes
Fold Change

Fold Change

GeneSymbol

(sip21o2 vs siNT)

adjusted p

(sip21o3 vs siNT)

adjusted p

Hfm1

-9.000967

4.17E-06

-9.551253

3.30E-06

Olfr356

-6.310875

0.000277

-6.7342

0.000213

Cnn1

-4.243251

2.60E-05

-4.088136

3.23E-05

Supt3

-3.3844

6.81E-05

-5.437286

4.28E-06

Cdkn1a

-2.804869

1.44E-07

-5.631165

1.15E-09

Ear7

-2.404938

1.27E-06

-2.886804

2.29E-07

Cdkn1a

-2.396397

4.53E-07

-3.167768

3.54E-08

Spint1

-1.945373

0.000275

-2.055021

0.00015

Spint1

-1.826354

5.97E-05

-1.544564

0.000716

Slc36a2

-1.781509

2.15E-05

-1.581507

0.00014

Ldhb

-1.71729

0.000103

-1.817892

4.60E-05

0610009E02Rik

-1.704009

0.000111

-1.568371

0.000405

Hpgd

-1.689703

7.12E-05

-1.759566

3.89E-05

Rcbtb2

-1.67373

4.01E-05

-1.513442

0.000225

Gm9733

-1.579973

0.000145

-1.708255

4.09E-05

Aldoc

-1.547172

6.71E-06

-1.556962

5.93E-06

Ppp1r9a

-1.54189

5.78E-05

-1.602184

2.88E-05

Sult1a1

-1.538296

0.000123

-1.649467

3.66E-05

Cib2

-1.522033

0.000125

-1.524215

0.000121
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Top 50 upregulated genes
Fold-change

Fold-change

GeneSymbol

(sip21o2 vs TCM)

adjusted p

(sip21o3 vs TCM)

adjusted p

Rrm2

-6.30647

3.17E-11

-7.95356

1.02E-11

Cdkn3

-6.28505

8.43E-10

-6.7755

5.76E-10

Pif1

-6.25111

2.88E-07

-8.06132

8.74E-08

Cxcl9

-5.11269

1.94E-05

-5.20062

1.78E-05

Hmmr

-4.85418

3.20E-05

-5.03176

2.65E-05

Hmmr

-4.31765

9.85E-05

-4.58722

7.12E-05

Mastl

-4.07957

9.67E-07

-4.21229

7.90E-07

Casc5

-3.96834

4.20E-05

-5.70901

5.80E-06

Pif1

-3.89545

2.18E-05

-4.68433

7.38E-06

Fancd2

-3.83321

2.11E-05

-4.92167

4.91E-06

Esco2

-3.67204

6.75E-06

-5.21945

8.15E-07

D17H6S56E-5

-3.60167

1.85E-08

-4.03994

8.27E-09

Mastl

-3.59825

4.18E-06

-4.83099

6.63E-07

Kif2c

-3.54186

1.80E-06

-4.37275

4.51E-07

Nek2

-3.52283

2.45E-08

-4.65013

3.78E-09

2010110K18Rik

-3.49874

1.67E-05

-4.71255

2.65E-06

Cdca2

-3.46713

0.000389

-4.92359

5.65E-05

Dlgap5

-3.41372

9.11E-08

-4.60248

1.20E-08

Xkr5

-3.39351

0.000359

-4.19719

0.000105

Foxm1

-3.38906

8.91E-08

-4.27792

1.76E-08

Prc1

-3.34136

3.54E-09

-4.5658

4.01E-10

Fbxo48

-3.29161

7.43E-06

-4.39264

1.10E-06
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Prc1

-3.25269

3.85E-07

-4.169

6.68E-08

Sgol1

-3.21025

8.10E-07

-3.98796

1.72E-07

BC030867

-3.20821

2.85E-08

-4.46017

2.75E-09

Depdc1a

-3.19559

0.000114

-3.78934

3.79E-05

Ckap2l

-3.17264

0.000106

-4.27054

1.62E-05

Kifc5b

-3.13167

0.000538

-4.41533

7.18E-05

Cenpf

-3.11857

7.64E-05

-3.32338

4.92E-05

Nusap1

-3.0947

2.82E-09

-4.11654

3.34E-10

Kif4

-3.09329

0.000319

-3.63404

0.000115

Kifc1

-3.0841

5.61E-05

-3.56142

2.08E-05

Kif18b

-3.08083

1.24E-05

-4.31059

1.26E-06

Prc1

-3.07972

0.0001

-3.4257

4.83E-05

Rad51

-3.07141

6.81E-08

-3.88828

1.15E-08

Pbk

-3.06893

7.85E-06

-3.44022

3.38E-06

Aspm

-3.06868

1.39E-06

-4.04615

1.89E-07

Sgol1

-3.0153

1.27E-07

-4.3219

9.18E-09

Rad51ap1

-3.01418

2.51E-08

-4.12435

2.40E-09

Ccna2

-3.01189

1.32E-06

-3.30825

6.34E-07

Rad51ap1

-2.99682

1.99E-06

-3.89215

2.92E-07

Efcab6

-2.99481

2.19E-05

-2.63158

6.16E-05

Fam64a

-2.98438

8.13E-08

-4.08292

7.76E-09

Shcbp1

-2.9764

0.000173

-3.27637

8.95E-05

Ccnb2

-2.97509

1.24E-08

-3.76131

1.98E-09

Ccnb1

-2.97083

2.59E-09

-4.04031

2.45E-10

Cdc20

-2.96576

7.65E-08

-3.80712

1.12E-08
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Ccnb1

-2.96254

2.22E-07

-3.57911

5.06E-08

Anln

-2.95577

1.58E-05

-3.15593

9.56E-06

Table 2.2: KEY RESOURCES
Sequences of siRNAs targeting p21 and CSF1
Clone Name

Target Gene ID

Sequence

mm.Ri.Cdkn1a.13.3

NM_007669

5'rCrUrGrArCrArGrArUrUrUrCrUrArUrCrArCrGrCrUrU

NM_001111099

rGrGrArGrUrGrArUrArGrArArA

NM_007669

5'rArCrArGrUrCrCrUrArCrUrGrArUrArUrCrA

NM_001111099

rGrArUrGrGrGrUrUrGrArUrArUrCrArGrU

NM_001113530

5'rGrCrArGrCrAGrUrUrGrArUrCrGrArCrArCrArUrUrUr

NM_007778

GrArCrUrGrUrCrGrArUrCrArA

mm.Ri.Cdkn1a.13.2

mm.Ri.Csf1.13.1

NM_001113529
mm.Ri.Csf1.13.2

siNC

NM_001113530

5'

NM_007778

rCrArGrGrUrGrGrArArCrUrGrCrCrArGrUrCrUrUrUrCr

NM_001113529

UrArUrArCrUrGrGrCrArGrUrU

Negative Control(DS na
NC1)

Primer:ROSA-CAG-ES-

This paper

5'CTAAAGAAGAGGCTGTGCTTTGGGGCTCVG

Primer:CAG-R2

This paper

5' CTCCACCCATTGACGTCAATGGAAAGTCCC

Primer:BGH-F3

This paper

5' CGACTGTGCCTTCTAGTTGCCAGCCATCTG

Primer:ROSA-R10

This paper

5' CACTTGTGGTCTTCAGACACACCAGAAGAG

Primer:ROSA-WT-F1

This paper

5'GTTATCAGTAAGGGAGTGCAGTGGAGTAG

Primer:ROSA-WT-R1

This paper

5'CCGAAAATCTGTGGGAAGTCTTGTCCCTCC

Primer:CAG-R2

This paper

5'CTCCACCCATTGACGTCAATGGAAAGTCCC

Primer:12427

(Deng et al., 1995)

5' GTTGTCCTCGCCCTCATCTA

PC-For
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Primer:12428

(Deng et al., 1995)

5' GCCTATGTTGGGAAACCAGA

Primer:12429

(Deng et al., 1995)

5' CTGTCCATCTGCACGAGACTA

Primer:oIMR3067

(Clausen

et

al., 5' CTTGGGCTGCCAGAATTTCTC

et

al., 5' CCCAGAAATGCCAGATTACG

et

al., 5' TTACAGTCGGCCAGGCTGAC

1999)

Primer:oIMR3066

(Clausen
1999)

Primer:oIMR3068

(Clausen
1999)

Antibodies
Name

Identifier

Clone#

Company

Dilution

CD45

RRID:AB_469625

30-F11

eBioscience

1:400

CD3e

RRID:AB_469315

145-2C11

eBioscience

1:200

CD4

RRID:AB_464900

RM4-4

eBioscience

1:200

CD8a

RRID:AB_2732919

53-6.7

BD Biosciences

1:200

Foxp3

RRID:AB_11218094

FJK-16s

eBioscience

1:100

CD19

RRID:AB_1659676

eBio1D3

eBioscience

1:200

CD11b

RRID:AB_657585

M1/70

eBioscience

1:400

CD11c

RRID:AB_1548652

N418

eBioscience

1:200

Ly6C

RRID:AB_1518762

HK1.4

eBioscience

1:400

Ly6G

RRID:AB_1186104

1A8

BioLegend

1:400

F4/80

RRID:AB_468798

BM8

eBioscience

1:400

MHCII

RRID:AB_1272204

M5/115.15.2

eBioscience

1:400

CD24

RRID:AB_464985

30-F1

eBioscience

1:200

CD44

RRID:AB_1272246

IM7

eBioscience

1:200
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CD62L

RRID:AB_11125577

MEL-14

BioLegend

1:100

Flt3
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Taqman

Mm01277042_m1
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Mm00432359_m1

CCNE1

Taqman

Mm01266311_m1

CCNA2

Taqman

Mm00438063_m1

IFIT3

Taqman

Mm01704846_s1

CD40

Taqman

Mm00441891_m1

IFNA1

Taqman

Mm03030145_gH

IFNB1

Taqman

Mm00439546_s1

IRF1

Taqman

Mm01288580_m1

CDKN1A

Taqman

Mm04205640_g1

CSF1

Taqman

Mm00432686_m1

Q-PCR primers
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CXCL1

Taqman

Mm04207460_m1

CXCL2

Taqman

Mm00436450_m1

IL-1a

Taqman

Mm00439620_m1

IL-1b

Taqman

Mm00434228_m1

IL-6
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TNF-a

Taqman

Mm00443258_m1
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Taqman
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Taqman

Mm00479410_m1

c-Myc
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Experimental Models
Strain

Source

Identifier

Mouse:B6.Cg-ROSA26tm1(LSL-p21-YFP)

This paper

N/A

Mouse:C57BL/6J

The Jackson Laboratory

Stock# 000664

Mouse:B6.129S6(Cg)-Cdkn1atm1Led

The Jackson Laboratory

Stock # 016565

Mouse:B6.129p2-lyz2tm1(cre)ifo

The Jackson Laboratory

Stock # 004781

Mouse:B6.p48-Cre;KrasLSL-G12D;Trp53fl/fl

i.e. N/A

KPC
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N/A

Software and Algorithms
Flowjo v10.7.2

Flowjo, L.L.C.

Flowjo, L.L.C.

Prism v9

Graphpad

www.graphpad.com

Docker

Rocker/rstudio:latest

https://hub.docker.com/r/rocker/rstudio

cumulusprod/cellranger:4.0.0

https://hub.docker.com/r/cumulusprod/cellrange
r/tags

HALO v3.2.1851 Indica Labs-High Plex Fv4.0.3

https://indicalab.com/products/high-plex-fl/

Indica Labs-Deconvolution v1.0.4
Cytobank

Cytobank, Inc

Wustl.cytobank.org

FACSDiva

BD Biosciences

RRID: SCR_001456

Zen

Zeiss

Zeiss.com

Morpheus

Broad Institute

https://software.broadinstitute.org/morpheus/

Fiji v2.0.0

ImageJ

R v3.6.3

R Core Team

https://cran.rproject.org/bin/windows/base/old/3.6.3/

Clusterprofiler (Wu et al., 2021)

https://github.com/YuLab-SMU/clusterProfiler

Seurat v 3.2.0(Stuart et al., 2019)

https://satijalab.org/seurat/

Harmony(Korsunsky et al., 2019)

https://github.com/immunogenomics/harmony

CATALYST(Nowicka et al., 2017)

https://github.com/HelenaLC/CATALYST

Chemicals and Recombinant Proteins
Reagent

Source

Identifier

CSF1 neutralizing antibody(Clone 5A1)

BioXCell

BE0204

CSF1R depleting antibody(Clone AFS98)

BioXCell

BE0213

PBS Liposomes & Clodronate Liposomes

Liposoma

CP-005-005
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Recombinant murine CSF1 peptide

Peprotech

315-02

Carboxyfluorescein succinimidyl ester(CFSE)

Invitrogen

C1157

Tamoxifen

Sigma-Aldrich

T5648

Halt Protease and Phosphatase Inhibitor

Thermo Scientific

78442

RIPA Buffer(10x)

Cell Signaling

UN3082

CD45 MicroBeads

Miltenyi Biotec

130-052-301

Resources

Source

Catalog number

Supersignal West Dura

Thermo

34075

FITC BrdU Flow Kit

BD Bioscience

557891

APC BrdU Flow Kit

BD Bioscience

557892

Proteome Profiler Mouse XL Cytokine Array

R&D systems

ARY028

E.Z.N.A. Total RNA Kit I

Omega

R6834-02

Taqman Gene Expression Master Mix

Thermo Fisher

4370074

qScript cDNA Supermix kit

Quantabio

95048-500

BOND Polymer Refine Detection Kit

Leica

DS9800

BOND Polymer Refine Red Detection Kit

Leica

DS9390

BOND Intense R Detection Kit

Leica

DS9263

Cytofix Kit

BD Bioscience

554655

MACS LS kit

Miltenyi

130042401

Mouse Macrophage Nucleofector Kit

Lonza

VPA-1009

Latex Beads-Rabbit IgG-PE Complex

Cayman

600541

Mouse M-CSF Matched Antibody Pair Kit

Abcam

Ab218788

Pierce BCA Protein Assay Kit

Thermo Scientific

23225

Commercial Assays
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DuoSet ELISA Mouse M-CSF

R&D system

DY416-05

DuoSet Ancillary Reagent Kit2

R&D system

DY008

88

2.5 Methods:
Murine PDAC models
Mice were maintained in the Laboratory for Animal Care barrier facility at the Washington
University School of Medicine. All studies were approved by the Washington University School
of Medicine Institutional Animal Studies Committee.
KPC mice (p48-Cre;KrasLSL-G12D;Trp53fl/fl) used in these studies have been rapidly bred
to the C57Bl/6J background in our laboratory using speed-congenics and further backcrossed
more than five times. All mice were housed, bred, and maintained under specific pathogen-free
conditions in accordance with NIH-AALAC standards and were consistent with the Washington
University School of Medicine IACUC regulations (protocols #20160265 and #19-0856).
The KP-1 cell line was derived from PDAC tissues of the 2.2-month-old p48-CRE+/LSLKrasG12D/p53flox/flox (KPC); the KP-2 cell line was derived from the 6-month-old p48-CRE+/LSLKrasG12D/p53flox/+ mice(KPfl/+C) (Jiang et al., 2016). The KI cell line was derived from the Pdx1Cre;LSL-KrasG12D;Ink/Arffl/fl as previously described (Mitchem et al., 2013). Cells were grown
on collagen-coated tissue culture flasks for < 12 passages, and were tested for cytokeratin-19,
smooth muscle actin, vimentin, and CD45 to verify their carcinoma identity and purity. The
PDA.69 cell line was a kind gift from Dr. Gregory L. Beatty and was maintained in tissue culture
flasks with DMEM supplemented with 1% glutamax and 0.167% gentamycin for less than 13
passages. To establish orthotopic PDAC models, either 50,000 or 200,000 KP-2 cells, and
10,000 or 50,000 PDA.69 cells in 50 μL of Cultrex (Trevigen, Gaithersburg, MD, USA) were
injected into the pancreas of 8–12-week-old C57BL/6 mice or transgenic mice according to
published protocols (Kim et al., 2009). Tumor-bearing mice were sacrificed when the palpable
tumor size was > 1 cm (21–27days).
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Other mouse models
The p21CE mouse was developed at the Washington University Mouse Embryonic Stem Cell
Core using the construct of Cdkn1a (p21, accession #NM_007669). Briefly, the construct
contained the p21 gene under the control of a CAG promoter and a lox-stop-lox case.
Downstream of the p21 gene, the construct also contained an internal ribosome entry site (IRES)
and YFP gene for visualization. The construct was then integrated into the ROSA locus of pure
C57/B6 mice (ROSA-CAG-LSL-p21-IRES-YFP) and injected into C57 blastocyst (p21+/wt).
Successful chimeras were selected and verified by DNA sequencing across ROSA junctions
(primers are listed in Table 2.2) and subsequent founder mice were identified via genomic PCR
(primers are listed in Table 2.2). Then, p21+/wt mice were crossed with LysMCre mice to
specifically induce p21 expression in macrophages. The resulting LysM+/+/p21+/wt mice are
termed “p21 constitutive expression” (p21CE) mice.

Tissue harvest
Mice were euthanized by intracardiac perfusion with 15 mL of phosphate-buffered saline (PBS)heparin under isoflurane anesthesia. Blood was obtained by cardiac puncture and deposited in
heparin-PBS (Alfa Aesar Lonza, Haverhill, MA, USA) solution. Blood was then incubated in red
blood cell lysis buffer (Biolegend, San Diego, CA, USA) for 10 min on ice and quenched with
1% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA, USA) containing PBS.
Normal and tumor tissues were manually minced and digested in 20 mL of Hank’s Balanced Salt
Solution (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 2 mg/mL of
collagenase A (Roche, Basel, Switzerland) and 1× DNase I (Sigma-Aldrich, St. Louis, MO,
USA) for 30 min (20 min for normal tissue) at 37°C with agitation. After digestion, the cell
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suspensions were quenched with 5 mL of PBS and filtered through 40 μm nylon mesh. The
filtered suspensions were then pelleted by centrifugation (1,800 rpm for 4 min at 4°C) and
resuspended in flow cytometry buffer PBS containing 1% bovine serum albumin (BSA) and 5
mM EDTA as a single cell suspension.

Flow cytometry
Following tissue digestion, single cell suspensions were blocked with rat anti-mouse
CD16/CD32 antibodies (eBioscience, Waltham, MA, USA) for 10 min on ice, and pelleted by
centrifugation. The cells were subsequently labeled with 100 µL of fluorophore-conjugated antimouse extracellular antibodies at recommended dilutions for 30 min on ice in flow cytometry
buffer. Intracellular staining was conducted using eBioscience Transcription Factor Staining
Buffer using the manufacturer’s recommended procedures. All antibodies are listed in Table 2.2.
For live analysis of YFP, fluorophore-labeled cells were analyzed immediately without fixation
on X-20 cytometers.
For proliferation assays, mice were injected with BrdU, 1 mg i.p. at 3 h prior to sacrifice.
A BD Biosciences Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA, USA) was used
following extracellular staining to stain for BrdU.
For experiments that measured T cell cytokines involving ex vivo stimulation, primary
cell suspensions were incubated in 96-well format (1M cells) with 1 μM Brefeldin A (Biolegend,
San Diego, CA, USA) and 2uM Monensin Solution ((Biolegend, San Diego, CA, USA) and 1X
Stimulation Cocktail (Ebioscience, San Diego, CA, USA) for 4 hours at 37 oC and 5% CO2.
After incubation, cells were resuspended in Fc block buffer and then labeled with fluorophoreconjugated anti-mouse antibodies as above.
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Human samples
Human PDAC samples were obtained from consenting patients diagnosed at Washington
University and the Siteman Cancer Center. Patients underwent pancreaticoduodenectomy. The
Washington University Ethics committee approved the study under IRB protocol #201704078.

Mass cytometry
Human tumor samples were collected on different days right after surgery and digested in
Hank’s Balanced Salt Solution supplemented with 2 mg/mL collagenase A (Roche), 2.5 U/mL
hyaluronidase (Sigma-Aldrich), and DNase I at 37°C for 30 min with agitation to generate single
cell suspensions. Cell suspensions were counted and stained in 5 μM cisplatin per million cells
for exactly 3 min on ice and washed with Cy-FACS buffer (PBS, 0.1% BSA, 0.02% NaN3, and 2
mM EDTA) twice. The cells were then incubated with FcR blocking reagent plus surfaceantibody cocktail for 40 min on ice. After incubation, surface marker-stained cells were washed
twice with Cy-FACS buffer. Cells were then fixed with 4% paraformaldehyde (PFA) for 10 min
on ice and permeabilized with permeabilization buffer containing the intracellular stain cocktail
(Invitrogen, Carlsbad, CA, USA) for 40 min. All antibodies are listed in Table 2.2. The cells
were then washed and fixed a second time in 4% PFA in PBS at 4°C at least overnight. One day
prior to acquisition, the cells were washed twice and stained with 200 μL of DNA intercalator
per million cells. Cells were acquired on a CyTOF2 mass cytometer (South San Francisco, CA,
USA) and were normalized with the MATLAB normalizer (v.7.14.0.739 run in MATLAB
R2012a)(Finck et al., 2013). The normalized data were uploaded into Cytobank and manually
gated to exclude normalization beads, cell debris, dead cells, doublets, and CD45- cells. The
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filtered sample from each individual specimen was then exported and batch normalized by the
date of acquisition using the R Cydar package NormalizeBatch function (mode = “range”) to
compute a quantile function from the pooled distribution of the input expression data (Lun et al.,
2017). In brief, batch expression was scaled between the upper and lower bounds of the pooled
reference distribution, with zero values fixed at zero. A total of 10,245 events per batch of
corrected sample was then visualized using the standard t-SNE algorithm in Cytobank.
Populations of interest were manually gated and verified based on lineage marker expressions.
For mouse samples in Fig. 7 F-I, seven mice per group were individually stained for
surface and intracellular stains (the antibodies are listed in Table 2.2) and fixed overnight as
described above. Each sample was then barcoded with a unique combination of palladium metal
barcodes using the manufacturer’s instructions (Fluidigm). Following bar coding, the cells were
pooled together and incubated overnight in 2% PFA containing 40 nM iridium nucleic acid
intercalator (Fluidigm). On the day of acquisition, the barcoded samples were washed and
suspended in water containing 10% EQ Calibration Beads (Fluidigm) before acquisition on a
CyTOF2 mass cytometer (Fluidigm). Sample barcodes were interpreted using a single cell
debarcoder tool (Zunder et al., 2015). FCS files were then uploaded to Cytobank and manually
gated to exclude normalization beads, cell debris, dead cells, and doublets. Classical T cells were
classified as CD45+, Cisplatin-, Thy1.2+, NK1.1-, TCR-, and TCR+. All T cells were exported
as new FCS files and analyzed using the R CATALYST package (Nowicka et al., 2017) in R,
version 3.8.2 (The R Project for Statistical Computing, Vienna, Austria). In brief, FCS files were
downsampled to equivalent cell counts, before clustering with the R implementation of the
Phenograph algorithm (Levine et al., 2015). All markers were used for clustering analysis except
markers used for T cell gating (see above). Dimensional reduction and visualization were
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performed using the UMAP algorithm (McInnes et al., 2020). Finally, differential cluster
abundance testing was performed with the R diffcyt package, utilizing a generalized linear mixed
model (Weber et al., 2019).

Macrophage depletion
In Fig. 2.3 F, 8–12-week-old C57BL/6 mice were orthotopically implanted with 200,000 KP-2
cells. When the tumor was palpable, mice were intraperitoneally treated with one dose of 1 mg
CSF1 neutralizing antibody (clone 5A1; BioXCell, Lebanon, NH, USA) and sacrificed at 12 and
24 h after treatments.
In Fig. 2.12, H - J, to deplete tissue resident macrophages, 8–12-weeks-old p21CE and
p21WT mice were implanted orthotopically with 50,000 KP-2 cells on day 0, then were treated
with three doses of CSF1 neutralizing antibody (1 mg, 0.5 mg, and 0.5 mg on days 3, 10, and 17)
and two doses of clodronate-containing liposomes (200 µL each on days 5 and 12). Control mice
were treated with the same doses/volumes of IgG (clone HRPN, BioXCell) and PBS liposomes.

In Vitro co-culture and siRNA treatment
All cell lines were maintained in DMEM (Lonza, Basel, Switzerland) supplemented with 10%
FBS (Atlanta Biological) and penicillin/streptomycin (Gibco, Gaithersburg, MD, USA). All cell
lines tested negative for mycoplasma.
Pancreatic fibroblasts were harvested from the pancreas of healthy 8-week-old C57BL/6
mice, passaged three times on tissue culture plates, and tested negative for mycoplasma. An
immortal pancreatic fibroblast cell line was established by passage more than 18 times. Soluble
factors in primary pancreatic fibroblasts and immortal pancreatic fibroblasts medium were
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measured, compared, and found to be similar. Bone marrow cells were obtained from both femur
and tibia of the mouse and differentiated for five days in DMEM supplemented with 10ng of
CSF1 (PeproTech, NJ, USA) for five days to generate BMDMs.
A total of 75,000 fibroblasts or 50,000 KP-2 cells or both cell types were co-cultured
with 100,000 BMDMs in 6-well cell culture plates (Costar, San Jose, CA, USA). BrdU was
added 6 h prior to harvest at each time point. For Transwell assays, 150,000 fibroblasts were
cultured in the Transwell assay with 200,000 BMDMs, and BrdU was added 6 h prior to harvest.
Small interfering RNAs (siRNAs) targeting mouse CSF1 and p21 were purchased from
Integrated DNA Technologies (Coralville, IA, USA). Sequences are listed in Table 2.2. The
siRNA transfections for primary BMDMs and pancreatic fibroblasts were performed using the
Mouse Macrophage Nucleofector™ Kit (Lonza) and Nucleofector™ 2b Device (Lonza) with
prewritten program Y-001 for BMDMs and V-013 for fibroblasts, following the manufacturer’s
instructions. RNA and protein from transfected primary cells were harvest 24 h after the
transfections.

Microarray and RT-qPCR analysis
Total RNA was isolated from BMDMs derived from p21CE, p21WT, or p21-/-, or from siRNA
targeting for p21-treated BMDMs using the E.N.Z.A. Total RNA Kit (Omega Chemicals,
Cowpens, SC, USA) according to the manufacturer’s instructions. Microarrays were performed
on p21 knocked-down BMDMs with the treatment of tumor-conditioned medium for 24 h. A
differential gene list was generated with detected fold-changes > 1.5, adjusted p < 0.05. The
filtered differential gene list was loaded into R and a hypergeometric test was used to compare
known catalogs of functional annotations (enricher) with an FDR of p < 0.05. Top differentially-
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regulated genes are listed in Table 2.1. RNAs from BMDMs of p21CE, p21WT, and p21-/- were
reversed-transcribed to cDNAs by using the qScript cDNA SuperMix (QuantaBio, Beverly, MA,
USA). Quantitative real-time PCR Taqman primer probe sets specific for targets listed in Table
2.2 (Applied Biosystems, Foster City, CA, USA) were used, and the relative gene expression for
each target was determined on a ABI7900HT quantitative PCR machine (Applied Biosystems)
using a Taqman Gene Expression Master Mix (Applied Biosystems). The threshold cycle
method was used to determine fold-changes of gene expressions normalized to Gapdh, Hprt, and
Tbp.

ELISA and the cytokine array
Conditioned media from fibroblasts and tumor cells were harvested after changing the medium
to 0.1% FBS for 24 h with > 80% confluency. The cytokine array were conducted by using a
Proteome Profiler Mouse XL Cytokine Array kit (R&D Systems, Minneapolis, MN, USA)
following the manufacturer’s instructions. The membranes from each conditioned medium were
placed in an autoradiography film cassette and exposed to X-ray filming for 5–8 min. Positive
signals were quantified by ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Conditioned media were concentrated using a Pierce Concentrator (Thermo Fisher Scientific)
based on the manufacturer’s instructions. CSF1 levels were measured by a Mouse M-CSF
Matched Antibody Pair Kit (ab218788) following the manufacturer’s instructions.

Single cell RNA sequencing
Normal pancreas tissues were taken from three 10-week-old B6 mice, processed to single cell
suspension as explained in the tissue harvest section, pooled together, and sorted for live

96

macrophages (CD45+CD11b+F4/80+CD3-CD19-Siglecf-Ly6G-Ly6C-7AAD-) by using an Aria II
cell sorter (BD Biosciences)
Pancreatic tumors were taken from three 1.5-month-old KPC mice, processed to a single
cell suspension, pooled, and sorted for live macrophages and DC-enriched populations
(CD45+CD3-CD19-SiglecF-Ly6G-7AAD-).
Orthotopic KP-2 tumors were taken from p21CE and p21WT mice, and three from each
genotype were pooled as one sample and sorted for live CD45+ cells (CD45+7AAD-). Two
libraries were created for each genotype.
Sorted cells from each sample were encapsulated into droplets and libraries were
prepared using Chromium Single Cell 3’v3 Reagent kits according to the manufacturer’s
protocol (10x Genomics, Pleasanton, CA, USA). The generated libraries were sequenced by a
NovaSeq 6000 sequencing system (Illumina, San Diego, CA, USA) to an average of 50,000
mean reads per cell. Cellranger mkfastq pipeline (10X Genomics) was used to demultiplex
illumine base call files to FASTQ files. Files from the normal pancreas, pancreatic tumors, and
orthotopic tumors were demultiplexed with > 97% valid barcodes, and > 94% q30 reads. YFP
sequences were inserted into the mm10 reference (v.3.1.0; 10X Genomics) using the Cellranger
Mkref pipeline. Afterwards, fastq files from each sample were processed with Cellranger counts
and aligned to the mm10 reference (v.3.1.0, 10X Genomics) or mm10 containing YFP for p21CE
orthotopic tumor samples and the generated feature barcode matrix.
Human scRNAseq data were obtained from a publicly available dataset (Peng et al.,
2019). FASTQ files were realigned to the human GRCh38 reference and generated feature
barcode matrix, including 24 PDAC samples and 11 normal samples. However, only 21 PDAC
samples and six normal samples successfully passed the Cellranger count function.
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Mouse scRNAseq data (mPDAC GEMM-1) used in Fig. 2.3 A,B and Fig. 2.4 L,M and
Fig. 2.10 F were obtained from a published paper (Hosein et al., 2019).

Mouse scRNAseq data analysis
The filtered feature barcode matrix from the normal pancreas, KPC pancreatic tumors, and
p21WT orthotopic tumors were loaded into Seurat as Seurat objects (Seurat v.3). For each Seurat
object, genes that were expressed in less than three cells and cells that expressed less than 1,000
or more than 8,000 genes, were excluded. Cells with greater than 6% mitochondrial RNA
content were also excluded, resulting in 9,821 cells for normal, 6,091 for KPC tumors, and
16,904 for orthotopic tumors. SCTransform with default parameters was used on each individual
sample to normalize and scale the expression matrix against the sequence depths and percentages
of mitochondrial genes. Cell cycle scores and the corresponding cell cycle phase for each cell
were calculated, and assigned after SCTransform based on the expression signatures for S and
G2/M genes (CellCycleScoring). The differences between the S phase score and G2/M score
were regressed-out by SCTransform on individual samples. Variable features were calculated for
each sample independently and ranked, based on the number of samples they were independently
identified (SelectIntegrationFeatures). The top 3,000 shared variable features were used for
multi-set canonical correlation analysis to reduce dimensions and identify projection vectors that
defined shared biological states among samples and maximized overall correlations across
datasets. Mutual nearest neighbors (MNNS; pairs of cells, with one from each dataset) were
calculated and identified as “anchors” (FindIntegrationAnchors). Multiple datasets were then
integrated based on these calculated “anchors” and guided order trees with default parameters
(IntegrateData). Principle component analysis (PCA) was performed on the 3,000 variable genes
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calculated earlier (function RunPCA). A UMAP dimensional reduction was performed on the
scaled matrix using the first 25 PCA components to obtain a two-dimensional representation of
cell states. Then, these defined 25 dimensionalities were used to refine the edge weights between
any two cells based on Jaccard similarity (FindNeighbors), and were used to cluster cells through
FindClusters functions, which implemented shared nearest neighbor modularity optimization
with a resolution of 0.3, leading to 21 clusters.
To characterize clusters, the FindAllMarkers function with logfold threshold = 0.25 and
minimum 0.25-fold difference and MAST test were used to identify signatures alone with each
cluster. The macrophage/monocytes (clusters 0, 1, 2, 4, 6, 13, and 17) were selected and the top
3,000 variable features were recalculated to recluster to a higher resolution of 1. Macrophages
were selected based on clusters with high expressions of known macrophage marker genes,
including Csf1r, C1qa, C1qb, and H2-Aa, and confirmed by the absence of Cd3e, Ms4a1, Krt19,
Zbtb46, and Flt3, and further confirmed by identifying DEGs associated with potential
macrophage clusters, when compared to known macrophage specific marker genes. In Fig. 2.1
M, we reran SCTransform without regressing-out cell cycle scores to visualize proliferating
macrophage clusters. In Fig. 2.4, K and L, monocyte clusters were removed based on
expressions of monocyte markers, Ly6c2, Plac8, and Vcan. Macrophages were then stratified
based on p21 expression into p21High (top 10%) and p21Low (bottom 10%), resulting in 219 of
p21High vs. 182 of p21Low TAMs in KPC tumor, and 475 of p21High vs. 526 of p21Low TAMs in
KP-2 orthotopic tumors. For GSEA comparisons, the log2 (fold-change) of all genes detected
with min.pct > 0.1 and past MAST test was used as a ranking metric. GSEA was performed
using GO terms, KEGG pathways, Reactome, and MSigDB gene sets with Benjamini-Hochberg
FDR < 0.05 in ClusterProfiler (Wu et al., 2021). For DEGs between the two groups in each
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mouse PDAC model, we filtered genes with a Bonferroni-corrected p-value < 0.05 and foldchange >1.2 or <0.8.
For the mouse dataset (Hosein et al., 2019), the filtered feature barcode matrices,
containing KIC, KPC, and KPFC, were processed similarly with major cell types annotated in
2.3 B. Macrophages were then selected and stratified based on p21 expressions into p21High (top
10%) and p21Low (bottom 10%), resulting in 263 of p21High TAMs vs. 237 of p21Low TAMs.
For p21CE and p21WT comparisons, the filtered feature barcode matrix was processed
similarly, ending with 16,931 cells for p21WT tumors, and 9,519 cells for p21CE tumors. Cell
cycle scores and the corresponding cell cycle phase for each cell were calculated and assigned
after SCTransform based on the expression signatures for S and G2/M associated genes
(CellCycleScoring). The top 3,000 variable genes, 25 dimensionalities, and resolution of 0.3
generated 19 clusters (Fig. 2.12, A and B) , including 16,093 cells for p21CE tumors and 8,996
cells for p21WT tumors. Each population, including macrophages (clusters 1, 3, 5, 12, 15, and
18), monocytes (cluster 2), DCs (clusters 4, 11, 9, and 16), neutrophils (cluster 14), and
eosinophils (cluster 0) were subsetted, at 15 dimensionalities and resolutions of 1 to generate Fig.
2.6 C and Fig. 2.7 A and Fig. 2.12 E. Cell cycle effects were also regressed-out when subsetting
on each cell type, except for macrophages. DEGs with minimum percentage > 0.1, a Bonferronicorrected p-value < 0.05. and fold-change > 1.3 or < 0.75 were considered significant. The log2
(fold-change) of all genes detected with minimum percentage > 0.1 and past MAST tests were
used as a ranking metric for GSEA analysis. Gene sets with FDR < 0.05 were considered
significant.
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Human scRNAseq data analysis
For the human dataset (Peng et al., 2019), cells with greater than 15% mitochondrial genes were
retained and cells that expressed less than 500 genes were excluded. SCTransform with default
parameters was used on each individual sample to normalize and scale the expression matrix
against sequence depth and percentage of mitochondrial genes. Cell cycle scores and the
corresponding cell cycle phase for each cell were calculated, then assigned after SCTransform
based on the expression signatures for S and G2/M genes (CellCycleScoring). The differences
between S phase scores and G2/M scores were regressed-out by SCTransform on individual
samples. Variable features were calculated for every sample in the dataset independently and
ranked

based

on

the

number

of

samples

they

were

independently

identified

(SelectIntegrationFeatures). The top 3,000 shared variable features were used for PCA. The
calculated PCA embedding of each cell was then used as an input for the soft k-means clustering
algorithm. Briefly, through iteration, the algorithm designated the cluster-specific centroids and
cell-specific correction factors corresponding to batch effects. The correction factors were used
to assign cells into clusters until the assignment was stable (RunHarmony). Afterwards, similar
steps were taken; UMAP reduction used the first 20 PCA components and FindClusters with a
resolution of 0.3, leading to 12 clusters (Fig. 2.3 D). Immune cell clusters (3, 4, 9, and 10) were
reclustered, reintegrated (RunHarmony), and UMAP reduction was used with a resolution of 0.5
to generate 11 clusters. The clusters were further grouped into NKT cells, Tregs, T cells, Myeloid
cells, and B cells in Fig. 2.1, G and H.
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The mpIHC
Mouse tissues were fixed in 10% formalin for 24 h and embedded in paraffin after graded
ethanol dehydration. Embedded tissues were sectioned into 6-µm sections and loaded into
BOND RXm (Leica Biosystems, Wetzlar, Germany) for a series of staining including F4/80, p21,
PDPN, Ki67, and CK19. Based on antibody host species, default manufacturer protocols were
used (IntenseR and Polymer Refine), containing antigen-retrieval with citrate buffer, goat serum
and peroxide block, primary antibody incubation, post-primary incubation, and chromogenically
visualized with an AEC substrate (Abcam, Cambridge, UK). Between each two cycles of
staining, the slides were manually stained for hemoxylin and eosin, then scanned by Axio
Scan.Z1 (Zeiss, Jena, Germany). The slides were then destained by a gradient of ethanol plus a
2% hydrochloride wash and blocked with extra avidin/biotin (Vector Laboratories, Burlingame,
CA, USA) and a Fab fragment block (Jackson Laboratory, Bar Harbor, ME, USA).
Images of the same specimen but different stains were cropped into multiple segments by
Zen software (Zeiss). Each segment was then deconvoluted (Deconvolution, v.1.0.4; Indica
Labs, Albuquerque, NM, USA) for individual staining and fused using HALO software (Zeiss)
with the default manufacturer’s settings. Markers of interest were pseudo-colored and quantified
through the High plex FL, v.4.0.3 algorithm (Indica Labs).

Statistical analysis
All statistical analyses were performed using GraphPad Prism software v8, with final input from
a Biostatistics core expert at Washington University. All data are representative of at least two
independent experiments, unless specifically noted. Sample size was pre-calculated to satisfy
power-requirements (with >85% confidence) in most experiments and is specified in the figure
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legends wherever applicable. Data are shown as mean ± s.e.m., unless otherwise noted. Normaldistribution of data was assessed using the D’Agostino–Pearson omnibus normality test in Prism.
Statistical tests such as unpaired parametric Student’s t-test, ANOVA analysis (Bonferroni
multiple comparison) or unpaired non-parametric Mann–Whitney U test were used appropriately
based on normality of data. For proximity analyses, the non-parametric Kolmogorov-Smirnov
test was used to distinguish differences in frequency distributions. p < 0.05 was considered
statistically significant for all studies. n.s. denotes not significant.
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Chapter 3: Conclusions and Future
Directions
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3.1 Conclusions:
Macrophage proliferation has been observed in several non-cancer pathological
conditions, including helminth infections (Jenkins et al., 2011), atherosclerosis (Tang et al.,
2015), and obesity-associated adipose tissues (Amano et al., 2014). In these conditions,
proliferation of macrophages, albeit under the control of different factors, is necessary to sustain
total macrophage numbers at each tissue site. In our studies, we found in pancreatic tumors that
macrophage proliferation was mainly driven by CAF-derived CSF1. These data implied that
although the general need for macrophage expansion was common, the activated signaling
pathways and resulting macrophage phenotypes were largely tissue- and context-dependent.
Stromal rich tumors may increase TAM numbers more frequently by local proliferation.
Interestingly, CSF1 levels were reported to be higher in the blood of patients suffering from
melanoma, breast cancer, or pancreatic cancer. In these patients and also in corresponding mouse
models, macrophages were found to be proliferative (Bottazzi et al., 1990; Franklin et al., 2014;
Tymoszuk et al., 2014). These data suggested that CSF1-driven macrophage proliferation was
common in multiple cancer types.
An earlier study examined the CSF1 effects on CSF1R-expressing human breast cancer
cell lines, and found that CSF1 inhibited cell proliferation through inducing p53 independent, but
MAPK-dependent, p21 expression (Lee et al., 1999). This result may seem contradictory to ours
as we showed CSF1 induced BMDM proliferation. However, we also showed that knockingdown p21 expression or constitutively expressing it promoted or inhibited macrophage
proliferation. These data suggested that CSF1 induction of p21 in macrophages acted as a
checkpoint for S phase entry. The ultimate cell cycle transit required additional signaling, and the
signals could be synthesized according to the expression level of p21. One group reported that
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Raf signal intensity determined either induction of DNA synthesis or inhibition of proliferation
in fibroblasts by p21Cip1 expression levels (Sewing et al., 1997). A recent study further showed
that p21 not only determined the cell cycle fate of mother cells but could also be carried into
daughter cells and regulated the proliferation after mitosis (Yang et al., 2017). Therefore, it is not
surprising that the p21 expression level is known to protect cells from chemotherapy-induced
apoptosis (Hsu et al., 2019).
Aside from p21’s canonical role as a cell cycle checkpoint, several groups reported its
role in regulating inflammation, with some contradictory results. One group demonstrated that
p21-/- mice were more sensitive to LPS-induced septic shock due to inflammation (Trakala et al.,
2009). Likewise, p21-/- mice showed enhanced experimental inflammatory arthritis and severe
articular destruction (Mavers et al., 2012). Contrastingly, in a serum transfer model of arthritis,
p21-/- mice were more resistant (Scatizzi et al., 2006). Furthermore, disruption of p21 attenuated
lung inflammation in mice (Yao et al., 2008). These data suggested that regardless of whether
p21 promoted or inhibited inflammation, it was established that p21 regulated inflammation. In a
chronic pancreatitis model, one study found that p21 expression was significantly increased
overall, while knocking-down its expression resolved inflammation and prevented pancreatic
injury through reducing the release of NF-B-mediated proinflammatory cytokines, such as
TNF-, IL-6, and CXCL1 (Seleznik et al., 2018). These data suggested that at least in the
pancreas, p21 played a role in promoting inflammation, independent of KRAS mutations that are
commonly observed in PDAC and are known to drive inflammation (Kitajima et al., 2016).
However, this study did not identify the main drivers for p21-mediated inflammation.
Macrophages are known to exhibit plasticity, which gives them the capability to quickly
respond to environmental challenges. Expression levels of p21 could be an important regulator in

106

macrophage plasticity. Expression of p21 inhibited macrophage activation during LPS-induced
septic shock, as p21-/- macrophage expressed higher levels of CD40 and enhanced activation of
NF-B (Trakala et al., 2009). One study further demonstrated that expression of p21 acted more
like a buffer system for inflammation as it could adjust the equilibrium between p65-p50 and
p50-p50 NF-B pathways to mediate macrophage plasticity in LPS treatment (Rackov et al.
2016). However, none of these studies investigated p21 effects on macrophage polarization in
tumor settings. From scRNAseq data, we showed that stratifying macrophages based on p21
expressions into p21Hi and p21Low resulted in two phenotypically distinct macrophages
independent of the cell cycle, with the first being more inflammatory. TNF- and NF-B were
upregulated when p21 expression was high, which is consistent with previous findings. We
further illustrated that constitutive expression of p21 in macrophages impaired their phagocytosis
capabilities in vitro, lowered expression of genes associated with antigen cross-presentation in
orthotopic PDAC tumors, and hindered cytotoxic T cell functions, which eventually led to faster
tumor progression. These observations are important because as we showed both stromal
interaction and therapeutic interventions targeting cell cycle could induce p21 expression in
TAMs and lead to an inflammatory yet immunosuppressive phenotype. Given TAMs are usually
abundant in TME, these p21-driven phenotypic changes could eventually lead to resistance for
treatments.
We also found that in human and mouse PDACs, although p21 expression was highest in
macrophages, it was expressed by other myeloid populations. If p21 regulates inflammatory
responses through NF-B in macrophages, it is possible that other immune cells mediate
inflammation, like granulocytes and neutrophils, which could also be polarized by p21 in a
similar way. One group observed that p21 expression in neutrophils regulated inflammation in
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infections (Martin et al., 2016). In addition, we observed that p21 expression was induced by
chemotherapy not only in macrophages, but also in other myeloid cells, which suggested that
inflammatory but immunosuppressive phenotypes could be further strengthened by myeloid
cells, in addition to macrophages.
Understanding how the TME and cancer cell intrinsic factors regulate macrophage tumor
supportive vs. tumor suppressive functions is critical to therapeutically targeting TAMs in cancer
patients. In total, our data suggested that CAF-induced macrophage proliferation was important
for sustaining TAM number and induction of p21, which also resulted in immunosuppression
and tumor progression. Lastly, expression of p21 in TAMs might sensitize tumors to CD40
agonist treatment.

3.2 Future Directions:
PDAC is highly infiltrated by immunosuppressive myeloid cells that mainly include MDSCs –
defined as CD11b+GR1+ in mice and CD11b+CD33+ in human – and tumor associated
macrophages – defined as F480+Gr1- in mice and HLA-DR+CD68+ in human (Balachandran et
al., 2019). It is well established that these myeloid cells could mediate immune escape and
support tumor growth through mechanisms discussed in Chapter 1 (Kumar et al., 2016).
Understanding the roles of these myeloid cells within the TME is an ongoing project for both
finding new therapeutical targets and improving existing chemo/immune therapies.
Could cell cycle status affect macrophage phenotypes?
This dissertation study adds a new aspect to the field, in which we showed that
macrophage intrinsic cell cycle machinery not only regulates its cell cycle but also affect its
phenotype. The resulting phenotypic changes could have profound impacts on tumor
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microenvironment and tumor growth. Conceptually, it is not hard to accept that the cell-cycle
status and macrophage function are connected, as both could be a result of environmental
stimuli. An unpublished study has shown that macrophage cell-cycle phase determined
chromatin accessibility and therefore its polarization tendency. Macrophages that are in S-G2/M
phase express more tissue remodeling genes but fewer IFN- response genes (Daniel et al.,
2021). This study is in line with our study that proliferation impaired macrophages are more
proinflammatory. However, this study and several other studies, mentioned in the previous
section, used different molecules to change the proliferation of macrophages, such as adding IL4, LPS, or CSF1 (Jenkins et al., 2013; Ubanako et al., 2019; Jaguin et al., 2013). These cytokines
inevitably activate multiple signaling pathways downstream of each receptor. Therefore, it is still
unclear if the relationships between cell-cycle events and phenotypic (polarization) changes are
correlated or causal. If cell-cycle directly affects macrophage phenotypic, which regulators are
the driving force?
Our studies start to address this fundamental question and provide direct evidence to
show that p21 expression regulates macrophage phenotypes through enhanced NF-B activation
at the baseline. It remained to be explored how p21 affects NF-B activation, whether it is
through promote accumulation of NF-B activating factors like phospho-P65 or through
degradation of inhibitory molecules like IB It is also unclear if p21 regulates other pathways
that contribute to this phenotype and how multiple pathways crosstalk, and how p21 might
function in balancing them.
Is p21 expressing macrophage senescent?
Furthermore, p21 expressing cells can be long lasting, as evident in using CD115-MerCre
mouse. The p21 labeled TAMs persist 60 days after the last tamoxifen pulse. This observation
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raises the question of whether we induced macrophages to undergo senescence by constitutively
expressing p21. The characteristics of senescent cells are non-proliferating, non-dying and
acquiring a senescence-associated secretory phenotype (SASP). Indeed, p21 has been used by
researchers along with p16 as markers for senescence. In a study published last year, the group
found that p21 is necessary for holding mouse embryonic fibroblasts in cell-cycle arrest and if
p21 expression levels could not return to normal, cells would undergo senescence and induce
SASPs, which subsequently recruits immune cells for clearance of these cells (Sturmlechner et
al. 2021). Our observations are consistent with senescence field as p21 constitutive expressing
TAMs are more inflammatory and secrete more inflammatory cytokines. However, it is also
worth pointing out that TAMs do not need to enter a permanent senescence state to be
inflammatory and immunosuppressive, as we found p21High TAMs in tumors from both human
and mouse acquire the same inflammatory gene signatures as TAMs with constitutive p21
expression. This observation is similar to other groups’ findings that p16High macrophages mimic
the senescent SASPs (Liu et al., 2019). In summary, p21 is necessary for entry of senescent state
and is indispensable for secretion of inflammatory mediators. However, the clear mechanistic
differences between the impacts of chronic p21 expression and short-term p21 expression on
TAMs, as well as the connections to senescence still remain to be further explored.
Could p21 expression in myeloid cells affect tumor resistance to treatments?
Several studies have reported that p21 expression levels in tumor cells determine cells
resistant to DNA damage induced by chemotherapy (Koster et al., 2010; Hsu et al., 2019;
Martinez et al., 2002). However, all these studies focused on p21 expression in tumor cells and
failed to access the expression on other myeloid cells. Interestingly, we found that p21
expression is preferentially increased in myeloid cells compared to tumor cells 24 hours after
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both GEM/PTX and Folrinox treatments. One group reported that Mo-MDSCs expressed high
levels of p21 and p16 in orthotopic lung tumors. Co-implantation of tumor cells with p21 and
p16 DKO Mo-MDSCs had slower tumor growth compared to wild-type MDSCs (Okuma et al.,
2017), suggesting in animal models p21 expression in Mo-MDSCs also drives tumor
progression. However, it is unclear what the reasons of p21 upregulation are, if we consider the
survival and maintenance of some MDSCs are not largely dependent on CSF1 signaling. The
effects of p21 upregulation in other MDSCs are not addressed in this dissertation but might play
a major role in driving tumor immunity especially after treatments. These questions are remained
to be understood at both the cellular and systematic levels.
Does p21 regulates macrophage metabolism?
Studies have shown that short-term food deprivation potently induced p21 expression in
organs including liver, pancreas and hypothalamic nuclei, through transcription factors Forehead
Box 0 family (FOX) (Tinkum et al., 2013). These transcription factors bind to the p21 promoter
and regulate its transcription during fasting. Knocking down p21 resulted changes in the levels of
serum free fatty acids (FFA) and triglyceride (TG). p21 is also reported to be regulated by
integrated stress response kinase GCN2 – a sensor for amino acid deficiency (Manu et al., 2019).
These data further consolidate p21 function as a master coordinator for various cellular events
and cell fate. It would be interesting to see if p21 levels directly affect macrophage metabolism
and on metabolites that are available within the TME. We saw consistent downregulation of
oxidative phosphorylation in p21High macrophages, but it is unclear whether this change is a
consequence of a more inflammatory TME or if it is the driving force for macrophage
phenotypes and if it directly affects tumor growth.
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